ࡱ> vv` xbjbjss d* d $ $$$Pt< 72@VL$ih "> K+d T 4 pYkڑ$6vPZ\07Lkkk HDhT^7 $?I$; I  EMPIRIC ANTIBIOTIC USE IN CRITICALLY ILL PATIENTS SUMMARY Inappropriate empiric antibiotic therapy is widespread and associated with increased mortality in critically ill patients. Initial antibiotic selection must account for a variety of host, microbiologic, and pharmacologic factors. Institution-specific data, such as susceptibility patterns, must also be considered. Tailoring antimicrobial therapy based upon culture and sensitivity results will help to reduce costs, decrease the incidence of superinfection, and minimize the development of resistance.  INTRODUCTION Inappropriate empiric antibiotic therapy is widespread and associated with increased mortality in critically ill patients. Although published consensus statements can provide general concepts by which to guide empiric antibiotic selection, they are limited by a failure to incorporate local pathogen susceptibility patterns. There is considerable variability in the frequency of infections, spectrum of potential pathogens, and susceptibility patterns between different ICUs as well as subsets of patients within the same ICU. Several factors must be considered when selecting empiric antimicrobial therapy: Patient-specific factors Presumed source of infection (i.e., blood, sputum, urine, intra-abdominal) Presence of co-morbid conditions (i.e., recent surgery or trauma, chronic illness) Previous antibiotic administration history Microbiological factors Identification of the most likely pathogens and their unit-specific susceptibility patterns Pharmacologic factors Potential drug toxicity (i.e. aminoglycosides) Bioavailability Distribution to the site of infection Any empiric antibiotic regimen should be reassessed and tailored as soon as culture and sensitivity results become available. This practice serves to reduce costs, decrease the incidence of superinfection and minimize the development of antimicrobial resistance. The empiric use of vancomycin deserves special consideration. Widespread antimicrobial therapy with this agent has contributed to a significant increase in vancomycin-resistant enterococcal (VRE) infections. The potential transfer of resistance to more virulent organisms such as Staphylococcus aureus and Staphylococcus epidermidis poses a significant public health threat. As a result, the Centers for Disease Control (CDC) has published recommendations for the prudent use of vancomycin in a document addressing the prevention and control of resistance (1). LITERATURE REVIEW Early Appropriate Antimicrobial Therapy A recent focus regarding antimicrobial therapy emphasizes the importance of early initiation of appropriate antibiotic therapy. Delays in effective antimicrobial coverage are associated with a detrimental impact on patient morbidity and mortality, with an increased risk of sepsis, higher costs, and increased ventilator days for patients with ventilator-associated pneumonia (VAP) (2). Tailoring of antibiotics once cultures are available may not compensate for initial inadequate therapy (Class II). In a prospective, cohort study of critically ill patients, the relationship between inappropriate empiric antimicrobial therapy and outcome was evaluated (3). Multivariate analysis demonstrated that inadequate antimicrobial treatment of nosocomial infections was a risk factor for hospital mortality (adjusted OR 4.22; p<0.001). VAP and bloodstream infections accounted for 89% of inadequately treated nosocomial infections. The most common gram positive and gram-negative organisms associated with inadequately treated VAP were oxacillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa, respectively. Candida species were the most common organisms responsible for inadequate treatment of bloodstream infections (Class II). Combination therapy does increase the likelihood of appropriate therapy for multi-drug resistant (MDR) pathogens. Therefore, initial coverage should include agents from different classes. Gram-negative coverage typically involves a (-lactam, fluoroquinolone or aminoglycoside. Quinolones demonstrate better lung penetration and less renal toxicity as compared to aminoglycosides. However, there is evidence supporting a trend towards increased survival with aminoglycoside-containing regimens (4) (Class II). For patients with severe sepsis, it is recommended that intravenous antibiotic therapy be started within the first hour of recognition of severe sepsis, after appropriate cultures have been obtained (5) (Class III). Risk Factors for Multi-drug Resistant (MDR) Pathogens When selecting empiric antimicrobial therapy, an assessment for risk of infection with MDR organisms must be made. Risk factors include admission following recent hospitalization or residency in a healthcare-associated facility. Additionally, patients who develop symptoms after five days of hospitalization and/or mechanical ventilation are also at risk for MDR pathogens. Trouillet and colleagues noted a series of variables increasing the risk for MDR VAP. These include a duration of mechanical ventilation greater than seven days, prior antibiotic use, and broad-spectrum antimicrobial therapy, specifically, third-generation cephalosporins, fluoroquinolones and carbapenems (6) (Class II). Combination versus monotherapy Combination therapy has been advocated to achieve synergy against Pseudomonas aeruginosa and to prevent the emergence of multi-drug strains. However, this practice remains controversial. Synergy has been demonstrated to be valuable in neutropenic or bacteremic patients (7) (Class II). A meta-analysis of prospective, randomized trials comparing the treatment of sepsis with (-lactam monotherapy or with a (-lactam and aminoglycoside combination regimen failed to demonstrate a significant benefit for combination therapy (8) (Class II). Of the 7,586 patients evaluated, 1,200 had sepsis from VAP or hospital-associated pneumonia (HAP). No advantage was found with combination therapy for the treatment of Pseudomonas aeruginosa. Combination therapy did not prevent the development of MDR strains and the use of aminoglycosides resulted in higher rates of nephrotoxicity. A summary of studies addressing this issue is provided in the table below. AuthorHilf et al. (7)Leibovici et al. (9)Study DesignProspective, multicenter study of consecutive patients (Class II)Prospective, observational (Class II)PopulationP. aeruginosa bacteremia including neutropenic patients (27%) Gram (-) bacteremia (single organism) including neutropenic patientsComparison(s)Combination ((-lactam + AG) vs. monotherapyCombination ((-lactam + AG) vs. monotherapy ((-lactam or AG) Comparisons were made for appropriate empiric & definitive therapyResults200 patients 93% received anti-pseudomonal therapy 70% received combination therapy No correlation between results of in vitro susceptibility & synergy testing and outcome were found Mortality: Combo (27%) vs. mono (47%); p=0.0232165 patients Mortality (Empiric therapy) Combo (19%) vs. (-lactam (17%); p=NS. Combo (19%) vs. AG (24%); p<0.01 Mortality (Definitive therapy) Combo (15%) vs.(-lactam (13%); p=NS Combo (15%) vs.AG (23%); p<0.01 Mortality ((-lactam vs AG) Higher mortality in all strata with AG except UTIAuthors ConclusionsThe use of combination therapy rather than monotherapy for bacteremia caused by P. aeruginosa is associated with improved survival.Mortality rates for non-neutropenic patients treated with combination therapy and those given a single (-lactam were similar. Treatment with an AG as a single agent was associated with a higher mortality than treatment with a (-lactam (except in patients w/ UTI). AuthorSiegman-Igra, et al. (10)Crabtree, et al. (11)Study DesignRetrospective (Class III)Prospective, observational (Class II)PopulationP. aeruginosa bacteremia including neutropenic patients (11%)Surgical patients with gram (-) infection including general surgery, trauma & transplant patientsComparison(s)Combo=fluoroquinolone OR 3rd generation cephalosporin OR imipenem-cilastatin + AG Monotherapy= fluoroquinolone OR 3rd generation cephalosporin OR imipenem-cilastatinAG containing regimen vs. no AGResults123 patients (57 with appropriate definitive therapy & available for analysis) Urinary & respiratory tract most common sources. Mortality: Combo (13%) vs. mono (14%); p=NS258 episodes 25.6% received AG Patients in AG group were more likely to be on HD Pneumonia was most common site of infection AG group hadmore Pseudomonal infections In the no AG group, quinolones & cephalosporins were most commonly used When combo therapy was used, the most common regimen was a penicillin + AG Mortality: AG (25.8%) vs. no AG (13.5%); p=0.02Authors ConclusionsMonotherapy with a quinolone, cephalosporin, or imipenem-cilastatin is as effective as combination therapy.Patients with gram (-) infections treated with AGs had a higher mortality It is difficult to determine whether or not the administration of combination gram-negative antimicrobial therapy is associated with a mortality benefit. This is not only due to a lack of well-designed trials, but also a lack of homogeneity across trials and the presence of conflicting results. Patient populations ranged from those with pure bacteremias due to P. aeruginosa to all infections with any gram-negative organism. Additionally, neutropenic patients were included to varying degrees and a broad range of age groups were evaluated. Although aminoglycosides were consistently evaluated as the second antimicrobial agent, this was not the case for the first agent. Traditionally, combination therapy is thought of as the addition of an aminoglycoside to a (-lactam agent; however, the literature addressing this issue encompasses several classes of (-lactams (penicillins, cephalosporins, and carbapenems) as well as fluoroquinolones. Until there is a well-designed trial evaluating a homogenous population with specific antimicrobial agents, this issue will remain unresolved. The decision to tailor to monotherapy should therefore be based on patient-specific factors and clinical judgment. Specific Infections Pneumonia Wunderink and colleagues retrospectively reviewed two prospective, randomized, double-blind studies comparing linezolid to vancomycin for the treatment of nosocomial MRSA pneumonia (12) (Class III). Clinical cure was defined as resolution of initial symptoms with radiologic studies indicating improvement or lack of progression. Over 1000 patients were enrolled, of which 160 had a respiratory culture positive for MRSA. Clinical cure rates were 59% (36/61) and 36% (22/62) for linezolid and vancomycin, respectively (p < 0.01). Given the relatively small number of patients and subjective nature of a key end point, this analysis does not conclusively demonstrate that linezolid is superior to vancomycin for the treatment of MRSA pneumonia. However, it should be considered when an alternative to vancomycin is needed. Inhaled polymyxin has been advocated as a therapeutic option for MDR Pseudomonas aeruginosa nosocomial pneumonia. In a case report of three patients, Hamer described an improvement in patient condition using colistin in conjunction with ceftazidime, aztreonam or gentamicin (13) (Class III). Given the limited data, colistin merits further investigation and may be considered when more conventional treatment options are limited. Bacteremia An emerging issue is the use of tigecycline for the management of bloodstream infections. Several reported cases highlight the development of bacteremia in patients receiving the drug for other indications (14). This agent has a large volume of distribution and undergoes rapid and extensive transfer from the bloodstream to the tissues. Due to time-dependent pharmacodynamics, it is important that serum concentrations are maintained above the MIC. The authors explain that the development of bacteremia may have resulted from inadequate serum concentrations and caution using tigecycline in patients with bloodstream infections caused by organisms with an MIC >1 mg/L (Class III). Intra-abdominal Infection It is important to remember that definitive management of intra-abdominal infections is source control and antimicrobial therapy is purely adjunctive. Key considerations for the selection empiric antimicrobial therapy in critically ill patients are highlighted in a review of this topic (15). Briefly, determination of the most likely infecting pathogens is dependent upon the classification of primary, secondary, or tertiary peritonitis. The source of contamination should also be considered. For example, infections arising from the upper gastrointestinal tract can be managed with an agent with aerobic, as opposed to aerobic and anaerobic, activity. Following the publication of the above review, tigecycline was approved for use in the management of complicated intra-abdominal infections caused by Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Enterococcus faecalis (vancomycin-susceptible isolates only), MSSA, MRSA and selected anaerobes (16). With this indication, the product information states that caution should be exercised when considering tigecycline monotherapy in patients with complicated intra-abdominal infections secondary to clinically apparent intestinal perforation. In phase 3 studies, six patients treated with tigecycline and two patients treated with imipenem-cilastatin that presented with intestinal perforations developed sepsis/septic shock. The six tigecycline patients had higher APACHE II scores (median=13) than the imipenem-cilastatin patients (APACHE II scores = 4 and 6). Due to differences in baseline APACHE II scores between treatment groups and small overall numbers, the relationship of this outcome to treatment cannot be established. The following literature provides additional information on this topic. The results of two phase 3, multicenter, double-blind, randomized trials comparing the efficacy and safety of tigecycline and imipenem-cilastatin in patients with complicated intra-abdominal infections were summarized in a pooled analysis (17). Entry criteria included adult patients requiring surgery to treat a complicated intra-abdominal infection. There were several criteria for exclusion, including preoperative suspicion of spontaneous bacterial peritonitis, simple cholecystitis, gangrenous cholecystitis without rupture, simple appendicitis, acute suppurative cholangitis, pancreatic abscess or infected necrotizing pancreatitis; APACHE II score >30; significant hepatic or renal disease; current intra-abdominal infection known to be caused by bacterial isolate(s) not susceptible to either study drug (e.g., P aeruginosa and P mirabilis); surgical procedure requiring that fascia or deep muscular layers be left open or planned abdominal reexploration. Patients were randomized to receive tigecycline 100mg, followed by 50mg IV Q12H or imipenem-cilastatin 500mg IV Q6H (or appropriate adjusted doses based on weight and renal function). The primary endpoint was clinical response at the test-of-cure visit for the modified intention to treat and microbiologically evaluable population. Secondary analyses evaluated bacteriologic response at the test-of-cure visit by patient and isolate. Complicated appendicitis was the most common diagnosis, accounting for approximately 50% of infections in both groups. The mean APACHE II score in both groups was 6. Although a number of study populations were evaluated at the test-of-cure visit, there was no significant difference in clinical cure rates between tigecycline (80.2%) and imipenem-cilastatin (81.5%) (p<0.0001 for noninferiority). Additionally, there were no significant differences for either of the secondary endpoints between groups. Table 1: Empiric Antibiotic Selection **Antibiotics should be tailored when susceptibilities become available** OrganismAntibioticAlternativeGram-positive organismsStaphylococci aureusCefazolin or VancomycinLinezolidCoagulase-negative staphylococciVancomycinLinezolidS. pneumoniaeCeftriaxoneMoxifloxacinEnterococcus faecalisAmpicillin +/- GentamicinVancomycin +/- GentamicinEnterococcus faeciumLinezolidQuinupristin/dalfopristin Gram-negative organismsSerratia*Piperacillin/tazobactam / Gentamicin (-lactam / Ciprofloxacin or Ciprofloxacin / AminoglycosidePseudomonas aeruginosa*Piperacillin/tazobactam / TobramycinAcinetobacter*Cefepime / GentamicinCitrobacter*Cefepime / GentamicinEnterobacter*Piperacillin/tazobactam / GentamicinE. coli (non-ESBL isolate)CefazolinGentamicinKlebsiella (non-ESBL isolate)CefazolinGentamicin or QuinoloneHaemophilus influenzaeAzithromycinCefuroximeE. coli or Klebsiella (ESBL producer)MeropenemStenotrophomonas maltophiliaTrimethoprim/sulfamethoxazoleTicarcillin/clavulanic acid * The SPACE pneumonic can be used to remember gram-negative organisms that should be double-covered until susceptibility results are available. Table 2: cdc recommendations for prudent vancomycin use (1)situations in which the use of vancomycin is appropriate or acceptableFor treatment of serious infections caused by beta-lactam-resistant gram-positive microorganisms. Vancomycin may be less bactericidal than beta-lactam agents for beta-lactam susceptible staphylococci. For treatment of infections caused by gram-positive microorganisms in patients who have serious allergies to beta-lactam antimicrobials. When antibiotic-associated colitis fails to respond to metronidazole therapy or is severe and potentially life-threatening. Prophylaxis, as recommended by the American Heart Association, for endocarditis following certain procedures in patients at high risk for endocarditis. Prophylaxis for major surgical procedures involving implantation of prosthetic materials or devices at institutions that have a high rate of infections caused by MRSA or MRSE. A single dose of vancomycin administered immediately before surgery is sufficient unless the procedure lasts greater than 6 hours, in which case the dose should be repeated. Prophylaxis should be discontinued after a maximum of two doses. Situations in which the use of vancomycin should be discouragedRoutine surgical prophylaxis other than in a patient who has a life-threatening allergy to beta-lactam antibiotics. Empiric antimicrobial therapy for a febrile neutropenic patient, unless initial evidence indicates that the patient has an infection caused by gram-positive microorganisms and the prevalence of infections caused by MRSA in the hospital is substantial. Treatment in response to a single blood culture positive for coagulase-negative staphylococcus, if other blood cultures taken during the same time frame are negative. Continued empiric use for presumed infections in patients whose cultures are negative for beta-lactam-resistant gram-positive microorganisms. Systemic or local prophylaxis for infection or colonization of indwelling central or peripheral intravascular catheters. Selective decontamination of the digestive tract. Eradication of MRSA colonization. Primary treatment of antibiotic-associated colitis. Routine prophylaxis for patients on continuous ambulatory peritoneal dialysis or hemodialysis. Treatment (chosen for dosing convenience) of infections caused by beta-lactam sensitive gram-positive microorganisms in patients who have renal failure. Use of vancomycin solution for topical application or irrigation.  Table 3: Antimicrobial Dosing Guidelines DrugNormal Renal Function (CrCl >50 mL/min)Renal Dysfunction (CrCl 10-50 mL/min)Renal Failure (CrCl <10 mL/min)Amikacin (Calculator available on www.surgicalcriticalcare.net)Conventional dosing (once daily dosing not recommended)7.5mg/kg IV Q8H Obtain peak and trough with 3rd dose7.5mg/kg IV Q12-24H Obtain peak and trough with 3rd dose7.5mg/kg IV x 1 dose Subsequent doses based on levelsCefazolin1-2gm IV Q8H1gm IV Q12H1gm IV Q 24HCefepime1gm IV Q6H1gm IV Q8-12H1gm IV Q24HCefuroxime1.5gm IV Q8H1.5gm IV Q8-12H1.5gm IV Q24HColistin (aerosolized)150mg aerosolized Q12HNo adjustment necessaryNo adjustment necessaryCiprofloxacin400mg IV Q8H400mg IV Q12-24H400mg IV Q24HClindamycin 600-900mg IV Q8HNo adjustment necessaryNo adjustment necessaryGentamicin (Calculator available on www.surgicalcriticalcare.net)High-dose, extended interval7mg/kg IV Q24H Obtain level 12 hours after doseNot recommendedNot recommendedConventional dosing2.5mg/kg IV Q8H Obtain peak and trough with 3rd dose2.5mg/kg IV Q12-24H Obtain peak and trough with 3rd dose2.5mg/kg IV x 1 dose Subsequent doses based on levelsLinezolid600mg IV Q12HNo adjustment necessaryNo adjustment necessaryMetronidazole500mg IV Q8HNo adjustment necessary500mg IV Q12HMeropenem500mg IV Q6H500mg IV Q6-8H500mg IV Q12HTobramycin (Calculator available on www.surgicalcriticalcare.net)High-dose, extended interval7mg/kg IV Q24H Obtain level 12 hours after doseNot recommendedNot recommendedConventional2.5mg/kg IV Q8H Obtain peak and trough with 3rd dose2.5mg/kg IV Q12-24H Obtain peak and trough with 3rd dose2.5mg/kg IV x 1 dose Subsequent doses based on levelsVancomycin (Calculator available on www.surgicalcriticalcare.net)Conventional dosing (once daily dosing not recommended)15mg/kg IV Q8H Obtain trough prior to 3rd dose15mg/kg IV Q12-24H Obtain trough prior to 3rd dose15mg/kg IV x 1 dose Subsequent doses based on levels Burn Patients (note: only applies to >20% TBSA in the initial hypermetabolic phase of injury)Cefazolin1-2gm IV Q6H1gm IV Q8H1gm IV Q12HGentamicin/Tobramycin (Calculator available on www.surgicalcriticalcare.net)Conventional dosing (once daily dosing not recommended)2.5-3mg/kg IV Q8H Obtain peak and trough with 3rd dose2.5-3mg/kg IV Q12-24H Obtain peak and trough with 3rd dose2.5-3mg/kg IV x 1 dose Subsequent doses based on levelsPiperacillin/tazobactamCrCl >40 mL/minCrCl 20-40 mL/minCrCl <20 mL/minPneumonia4.5gm IV Q6H3.375gm IV Q6H2.25gm IV Q6HOther infections3.375gm IV Q6H2.25gm IV Q6H2.25gm IV Q8HVancomycin15mg/kg IV Q6H Obtain trough prior to 3rd dose15mg/kg IV Q8-12H Obtain trough prior to 3rd dose15mg/kg IV x 1 dose Subsequent doses based on levels REFERENCES Recommendations for preventing the spread of vancomycin resistance: Recommendations of the hospital infection control practices and advisory committee (HICPAC). MMWR 1995;44(RR12):1-13. Irequi M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122:262-268. Kollef MH, Ward S, Sherman G, et al. Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices. Crit Care Med 2000; 28:3456-64. Fowler, RA, Flavin KE, Barr J, et al. Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia. Chest 2003;123:835844. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-73. Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157:531-9. Hilf M, Yu VL, Sharp J, et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989;87:540-546. Paul M, Benuri-Silbiger I, Soares-Weiser K, et al. (-lactam monotherapy versus (-lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomized trials. BMJ 2004; 328: 668-72. Leibovici L, Paul M, Poznanski O, et al. Monotherapy versus (-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997; 41:1127-1133. Siegman-Igra Y, Ravona R, Primerman H, et al. Pseudomonas aeruginosa bacteremia; an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy. Int J Infect Dis 1998; 2:211-215. Crabtree TD, Pelletier SJ, Gleason TG, et al. Analysis of aminoglycosides in the treatment of gram-negative infections in surgical patients. Arch Surg 1999; 134:1293-1299. Wunderink RG, Rello J, Cammarata SK, et al. Analysis of two double-blinded studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124:1789-97. Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multi-drug resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 2000; 162:328-30. Peleg AY, Potoski BA, Rea R, et al. Acinetobacter baumannii bloodstream infections while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007; 59:128-131. Marshall JC, Innes M. Intensive care unit management of intra-abdominal infection. Crit Care Med 2003:31:2228-2237. Tygacil Product Information. Wyeth Pharmaceuticals, Philadelphia, PA. July 2006. 17. Babinchak T, Ellis-Grosse E, Dartois N, et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical trial data. CID 2005; 41:S354-67.  EMBED Visio.Drawing.6       PAGE 8 Approved 5/08/2007 DISCLAIMER: These guidelines were prepared by the Department of Surgical Education, Orlando Regional Medical Center. They are intended to serve as a general statement regarding appropriate patient care practices based upon the available medical literature and clinical expertise at the time of development. They should not be considered to be accepted protocol or policy, nor are intended to replace clinical judgment or dictate care of individual patients. Empiric antibiotic selection should be based on local susceptibility patterns of microorganisms.  PAGE 1 Approved 5/08/2007  PAGE 9 Approved 5/08/2007 DRAFT DRAFT DRAFT DRAFT DRAFT DRAFT DRAFT This guideline is under development EVIDENCE DEFINITIONS Class I: Prospective randomized controlled trial. Class II: Prospective clinical study or retrospective analysis of reliable data. Includes observational, cohort, prevalence, or case control studies. Class III: Retrospective study. Includes database or registry reviews, large series of case reports, expert opinion. Technology assessment: A technology study which does not lend itself to classification in the above-mentioned format. Devices are evaluated in terms of their accuracy, reliability, therapeutic potential, or cost effectiveness. LEVEL OF RECOMMENDATION DEFINITIONS Level 1: Convincingly justifiable based on available scientific information alone. Usually based on Class I data or strong Class II evidence if randomized testing is inappropriate. Conversely, low quality or contradictory Class I data may be insufficient to support a Level I recommendation. Level 2: Reasonably justifiable based on available scientific evidence and strongly supported by expert opinion. Usually supported by Class II data or a preponderance of Class III evidence. Level 3: Supported by available data, but scientific evidence is lacking. Generally supported by Class III data. Useful for educational purposes and in guiding future clinical research.  PAGE 5 RECOMMENDATIONS Level 1 None Level 2 Direct empiric antimicrobial selection at the most likely source of infection based upon clinical and microbiological data. Perform a risk assessment for the presence of multi-drug resistant organisms by reviewing the patients prior microbiologic data and antimicrobial use. Consider initiating antifungal therapy in patients at risk (see Management of Candida Infections in Surgical Patients guideline). Select combination therapy with agents from different classes for initial gram-negative coverage to increase the likelihood of susceptibility. Level 3 Perform focused diagnostic tests and procedures according to the Fever Assessment Guidelines. For patients with severe sepsis, initiate empiric antimicrobial agents within one hour. Tailor antibiotics based on culture and susceptibility results. For gram-negative infections, there is insufficient evidence to support routine combination therapy to achieve synergy or prevent resistance. In the absence of a clear survival advantage to combination gram-negative coverage, the decision to tailor antibiotic administration to monotherapy should be based on patient-specific factors. 2;5 6 7 D ^ _ BCSTaz{CI04J[b$?Ľӄӄӄ||hN OJQJh 6OJQJh 56OJQJ"hh56CJ OJQJaJ hh 56\ hN 5\ h 5\ h5\hOJQJh OJQJ h CJjh CJUmHnHu h 5h h CJ -23;5 7 D V W _ CTz$ & Fa$$ & Fa$$ & Fa$$a$$a$$a$$a$ l!txab $Ifgd $$Ifa$ $$Ifa$gd$a$ $ !a$gds$a$gds$a$gds@A_` "!$!.!/!=!m!n!!!!!!qhN hCJOJQJ^Jh6CJOJQJ]^JhhCJOJQJ^JhCJOJQJ^JhOJQJh5CJOJQJ^Jh 6OJQJh 56OJQJh 5OJQJ\h 6CJOJQJ]^Jh OJQJ jbh OJQJ' #!qeYP $$Ifa$ $$Ifa$gdN $$Ifa$gdkd$$IflFF$F t06    44 lal#!$!/!n!!!qe\SG $$Ifa$gd $Ifgd $IfgdN $$Ifa$gdkdr$$IflFF$F t06    44 lal!!!!,"o"qe\SS $Ifgd $IfgdN $$Ifa$gdkd$$IflFF$F t06    44 lal!!!!!!""n"o"p"x"""/#0#I#J#^#_#m#######$$6$7$B$ǿ埘}mZm}mZm}% jbh(h5CJOJQJ^Jh(h5CJOJQJ^Jh5CJOJQJ\^Jhh5h hhh(h6CJOJQJ]^Jh5CJOJQJ^JhOJQJhhCJOJQJ^JhN hCJOJQJ^JhCJOJQJ^J jbhCJOJQJ^Jo"p"x""""/#0#_#qe\\\\SS $Ifgd $IfgdN $$Ifa$gdkdV$$IflFF$F t06    44 lal_#m######$6$7$R$$$hkd$$IflFF$F t06    44 lal $Ifgd]- B$C$R$u$$$$$$$$%%%%&&%&&&'&(&.&/&H&I&^&`&l&m&&&&&϶ttl`X`XXh(OJQJh(CJOJQJ^JhN OJQJ jbhCJOJQJ^JhhCJOJQJ^Jh6CJOJQJ]^Jh5CJOJQJ^JhOJQJhCJOJQJ^Jh(5CJOJQJ^Jh(h5CJOJQJ^Jh5CJOJQJ\^J" jbh5CJOJQJ\^J $$$%%&&'&(&SN$a$kd:$$IflFF$F t06    44 lal $Ifgd $IfgdN $$Ifa$gd(&/&I&_&`&m&&&Pkd$$IflFF$F t06    44 lal $Ifgd]- $$Ifa$gd]- $$Ifa$gd]-&&&&Y'qe\P $$Ifa$gd( $Ifgd $$Ifa$gd]-kd$$IflFF$F t06    44 lal&&&&X'Z'g'h'''''((.(0(8((((((s)))*)*N*O*d*+++坖}n^VhOJQJh(h(5CJOJQJ^Jh(h(CJOJQJ^Jh(6CJOJQJ^Jhh(5h( h(5\h(h(\hh(CJOJQJ^Jh(CJH*OJQJ^Jh(5CJOJQJ^Jh(OJQJhN h(CJOJQJ^Jh(CJOJQJ^Jh(6CJOJQJ]^J Y'Z'h'''(/(qe\\\S $Ifgd( $Ifgd $$Ifa$gd]-kd$$IflFF$F t06    44 lal/(0(8(((((()qe\\\SJJ $Ifgd( $Ifgd $Ifgd $$Ifa$gd]-kd$$IflFF$F t06    44 lal)6)b)))**N*O*d*h\ $$Ifa$gd]-kdt$$IflFF$F t06    44 lal $Ifgd( d**+++/////_ZZZZZR $a$gds$a$kd$$IflFF$F t06    44 lal $Ifgd( $Ifgd]- +,,#.$...//////h0q0u0063G3{334445577777::::h;;;>Ͻڡypcch 6OJQJ\^Jh 5OJQJh >*OJQJ\]^Jh 5OJQJ]^Jh OJQJ\]^Jh h 5OJQJ\h >*CJOJQJ^J"h[ h[ 56CJ OJQJaJ h 56OJQJh[ OJQJ jbh OJQJh 6OJQJ]h OJQJ&/5363444777Q:R:>>BB[D\DWFXFYFFFFF $$Ifa$ !$a$ $h^ha$gds$a$gdsgds$a$gds>B!B%B0BWFYFFFFFFFFGGG>G?G`GuGvGGGGGGGGGG"H#H$HHGHmHnHHHHHHHڟڙڐڐڐڐڃ~ڟsڟ jbh OJQJ h >* h[ >*h>OJQJh 6OJQJ h CJh 56OJQJh 5B*OJQJphh B*phh B*OJQJphh 5B*OJQJphh 5OJQJh OJQJh 6OJQJ^Jh OJQJ^J-FFFFF $$Ifa$tkdX$$Ifl4      $$  t 04 lalf4p FFGwn $$Ifa$kd$$Ifl      F\ $\  ~ t0    4 lalGGG4G>G $$Ifa$ $$Ifa$dkd$$Ifl4      $$ t04 lalf4>G?G`GkGuGwqhh $$Ifa$$IfkdD$$Ifl      F\ $\  ~ t0    4 laluGvGGGGwqhh $$Ifa$$Ifkd$$Ifl      F\ $\  ~ t0    4 lalGGGGGwqhh $$Ifa$$Ifkd$$Ifl      F\ $\  ~ t0    4 lalGGGH"Hwqhh $$Ifa$$Ifkd] $$Ifl      F\ $\  ~ t0    4 lal"H#H$H* h[ 6>*h>6OJQJmHsHhsh 6OJQJmHsHhsh CJmHsHh 5OJQJh OJQJh 6OJQJh 56OJQJ*III2I3Itnee $$Ifa$$Ifkd $$Ifl4      F\ $\  ~ t0    4 lalf43I4IBIgIhItnee $$Ifa$$Ifkd $$Ifl4      F\ $\  ~ t0    4 lalf4hIiIIIItkbb $$Ifa$ $$Ifa$kdH$$Ifl4      F\ $\  ~ t0    4 lalf4IIIIItnee $$Ifa$$Ifkd$$Ifl4      F\ $\  ~ t0    4 lalf4IIII Jtnee $$Ifa$$Ifkd$$Ifl4      F\ $\  ~ t0    4 lalf4 J J1J;Jgkd$$Ifl$$ t0644 lal$If UUUUIUUUUUUUUV VV6V8V=VRVoVqVvVVVVVVVV WWWDW̻rrcRcrcRcrcrrr h>6CJH*OJQJ^JaJh>6CJOJQJ^JaJh>CJOJQJ^JaJh>OJQJ^J h>h>CJOJQJ^JaJ h>56CJOJQJ^JaJh>5CJOJQJ^JaJ hsh OJQJ^JmH sH +hsh 5CJOJQJ^JaJmH sH h h OJQJ^Jh 5CJOJQJ^JaJ UUU^U $Ifgd>kd$$Ifl\X l$X p$ t0644 lalUU VV>VJVRVwVVV~~~~~~~ $$Ifa$gd]- & F"$Ifgd>gkd$$Ifl$$ t0644 lal VVVVVV^XLLL $$Ifa$gd>$Ifkdi$$Ifl\X l$X p$ t0644 lalVVVVW W^XLLL $$Ifa$gd>$Ifkd2$$Ifl\X l$X p$ t0644 lal WWW&W6WDW^XLLL $$Ifa$gd>$Ifkd$$Ifl\X l$X p$ t0644 lalDWEW\WsWWW^XLLL $$Ifa$gd>$Ifkd$$Ifl\X l$X p$ t0644 lalDWEW\WWWWWWW-X.X:XnXoXpXqXXXXXY Y"Y'Y6CJH*OJQJ^JaJh>6CJOJQJ^JaJ h>h>CJOJQJ^JaJ h>56CJOJQJ^JaJh>CJOJQJ^JaJh>5CJOJQJ^JaJh>OJQJ^J;WWWWWW^XLLL $$Ifa$gd>$Ifkd$$Ifl\X l$X p$ t0644 lalWWWWWX-X\VVJJJ $$Ifa$gd>$IfkdV$$Iflx\X l$X p$ t0644 lal-X.XpX^U $Ifgd>kd#$$Ifl\X l$X p$ t0644 lalpXqXXXXXX~~~~ $$Ifa$gd> & F"$Ifgd>gkd$$Ifl$$ t0644 lalXXXY(Y4Y & F"$Ifgd>kd{$$Ifl\X l$X p$ t0644 lalp aYvYYYYYYYLF$IfkdQ$$Ifl\X l$X p$ t0644 lalp $$Ifa$gd>YYYYZ"Z^XLLL $$Ifa$gd>$Ifkd'$$Ifl\X l$X p$ t0644 lal"Z#Z-Z:ZIZWZ^XLLL $$Ifa$gd>$Ifkd$$Ifl\X l$X p$ t0644 lalWZXZZ^U $Ifgd>kd $$Ifl\X l$X p$ t0644 lalZZZZZZ[~~~~ $$Ifa$gd> & F"$Ifgd>gkd!$$Ifl$$ t0644 lal[ [[&[K[W[_[[XK????? $$Ifa$gd> & F"$Ifgd>kd"$$Ifl\X l$X p$ t0644 lalp [[[[[LC $Ifgd>kd"$$Ifl\X l$X p$ t0644 lalp $$Ifa$gd>[[[[[[5\6\E\]\_\e\x\\\\\\\\\-].]8]\]]]t]]]Ķ𶧖Ēyq_K_&h59h5956CJOJQJ^JaJ#h59h595CJOJQJ^JaJh>CJaJh>5CJaJ h>5h>56CJaJh59 h>6CJH*OJQJ^JaJh>6CJOJQJ^JaJh>CJOJQJ^JaJh>OJQJ^J h>h>CJOJQJ^JaJ h>56CJOJQJ^JaJh>5CJOJQJ^JaJ[[6\E\e\p\x\\\\uuuuuuu $$Ifa$gd> & F% 8$If^gd59gkd#$$Ifl$$ t0644 lal \\\-]^\V$Ifkd>$$$Ifl\X l$X p$ t0644 lal-].]8]E]P]\]yyy $$Ifa$$Ifwkd%$$Ifl$$  t 0644 lalp \]]]]^U $Ifgd59kd%$$Ifl\X l$X p$ t0644 lal]]]]]]^^^1^N^P^U^m^^^^^^__K_L_W_f_~________³³³rrjaVajaVajh596CJH*aJh596CJaJh59CJaJh59CJOJQJ^JaJ h595h595CJOJQJ^JaJh595CJaJ h>5 h>6CJH*OJQJ^JaJh>6CJOJQJ^JaJh>CJOJQJ^JaJh>5CJaJh59CJ^JaJh59h595CJaJ h59h59CJOJQJ^JaJ ]]]]^)^1^V^m^^xxxxxxx $$Ifa$ & F% 8$If^gd59gkdj&$$Ifl$$ t0644 lal ^^^^^^^XLLL $$Ifa$gd]-$Ifkd&$$Ifl\X l$X p$ t0644 lal^^^^__^QEEE $$Ifa$gd]- & F"$Ifgd]-kd'$$Ifl\X l$X p$ t0644 lal__ _/_=_K_^QEEE $$Ifa$gd]- & F"$Ifgd]-kdq($$Ifl\X l$X p$ t0644 lalK_L_W_f______^XOOOOOO $$Ifa$$Ifkd4)$$Ifl\X l$X p$ t0644 lal________````Va\aa bbbbb`cnccccd]dtdddd e e'e(eeeee f f}fffff[gҳҚҏҳ҄҄u҄ҏҚhsh OJQJmHsH jbh OJQJh 6OJQJ]hsh OJQJmH sH h OJQJ^Jh 6OJQJ]^Jh OJQJ]h 6OJQJh OJQJh>h h 5 h595h59CJaJh596CJ^JaJ._____`oabb^\ZUMMMM$ & Fa$$a$kd)$$Ifl\X l$X p$ t0644 lalbc&ddef}g-hhi`jj)klll l"l#l%l&l(l)l+l,l$a$gdsh7$8$H$^h` & F7$8$H$$ & Fa$[glg hh-hZhhhhhhhPigiiiiiii7jNjjj)k.k]kkklllllllll l!lҺҺҺҫҺҖvnfjh]-Uj*hsUj=I hsUVhsjhsUh 5OJQJh hsh OJQJ^JmH sH hsh OJQJmH sH h 6OJQJ^Jh 6OJQJ]^Jh OJQJ^J hsh OJQJ^JmHsHh OJQJh 6OJQJ]'!l#l$l&l'l)l*l,l-l.l4l5l6l7lAlJlKlLlnzn|n}n~nnnnnnnnnnnnnnnnnoo4o^ohoopjppOq{qrrXsasҹꨵҹܹh 5CJOJQJh 56CJOJQJh OJQJh 56CJOJQJh h_"v0JOJQJh590JOJQJmHnHuh 0JOJQJjh 0JOJQJUh CJOJQJjh]-Uh]-5,lKlLlnzn{n|nnnnnnoo,o $dN$a$  !$gd_"v-$ x$d%d&d'dNOPQa$gd_"v-$ x$d%d&d'dNOPQa$gd_"v !$,o^oojpNqOqsqrXstt t!t"t#t$t%t&t't7t?t $ & Fa$gd_"v$a$gd_"v $ !$a$ $$dNa$$ & F L$dN^`La$astttttttt t!t'tDtEttt#u1uBu`uuu v"vdvsvtvuvvvvvwwwwwxx2xUxWxnxxxxxx򸭸hT3h_"vhT3hT3CJ aJ hT3h h]-h OJQJh 0JOJQJmHnHuh 0JOJQJjh 0JOJQJUh h CJOJQJ/?tDtEtMttauutvuv}vv5wuwxxxxx$a$gds $ & Fa$gd_"v $ & Fa$gd_"v$a$gd_"v $ & Fa$gd_"v. 0 0/ =!"#$% 2 0 0&P/ =!"#$% p$$Ifl!vh5F55#vF#v:Vl t6,5F5alp$$Ifl!vh5F55#vF#v:Vl t6,5F5alp$$Ifl!vh5F55#vF#v:Vl t6,5F5alp$$Ifl!vh5F55#vF#v:Vl t6,5F5alp$$Ifl!vh5F55#vF#v:Vl t6,5F5alp$$Ifl!vh5F55#vF#v:Vl t6,5F5alp$$Ifl!vh5F55#vF#v:Vl t6,5F5alp$$Ifl!vh5F55#vF#v:Vl t6,5F5alp$$Ifl!vh5F55#vF#v:Vl t6,5F5alp$$Ifl!vh5F55#vF#v:Vl t6,5F5alp$$Ifl!vh5F55#vF#v:Vl t6,5F5alp$$Ifl!vh5F55#vF#v:Vl t6,5F5al$$Ifl!vh5$#v$:V l4  t 05$4alf4p $$Ifl!vh5\ 5 5~ #v\ #v #v~ :V l t05\ 5 5~ 4al$$Ifl!vh5$#v$:V l4 t05$4alf4$$Ifl!vh5\ 5 5~ #v\ #v #v~ :V l t05\ 5 5~ 4al$$Ifl!vh5\ 5 5~ #v\ #v #v~ :V l t05\ 5 5~ 4al$$Ifl!vh5\ 5 5~ #v\ #v #v~ :V l t05\ 5 5~ 4al$$Ifl!vh5\ 5 5~ #v\ #v #v~ :V l t05\ 5 5~ 4al$$Ifl!vh5\ 5 5~ #v\ #v #v~ :V l t05\ 5 5~ 4al$$Ifl!vh5$#v$:V l4 t05$4alf4$$Ifl!vh5\ 5 5~ #v\ #v #v~ :V l4 t0+5\ 5 5~ 4alf4$$Ifl!vh5\ 5 5~ #v\ #v #v~ :V l4 t0+5\ 5 5~ 4alf4$$Ifl!vh5\ 5 5~ #v\ #v #v~ :V l4 t0+5\ 5 5~ 4alf4$$Ifl!vh5\ 5 5~ #v\ #v #v~ :V l4 t0+5\ 5 5~ 4alf4$$Ifl!vh5\ 5 5~ #v\ #v #v~ :V l4 t0+5\ 5 5~ 4alf4$$Ifl!vh5\ 5 5~ #v\ #v #v~ :V l4 t05\ 5 5~ 4alf4$$Ifl!vh5\ 5 5~ #v\ #v #v~ :V l4 t05\ 5 5~ 4alf4$$Ifl!vh5\ 5 5~ #v\ #v #v~ :V l4 t05\ 5 5~ 4alf4$$Ifl!vh5\ 5 5~ #v\ #v #v~ :V l4 t05\ 5 5~ 2s2:4alf4$$Ifl!vh5\ 5 5~ #v\ #v #v~ :V l t05\ 5 5~ 4al$$Ifl!vh5$#v$:V l t05$4al$$Ifl!vh5$#v$:V l  t 05$4alp $$Ifl!vh5$#v$:V l t05$/ 4al$$Ifl!vh5$#v$:V l  t 05$4alp $$Ifl!vh5$#v$:V l t05$4al$$Ifl!vh5$#v$:V l t065$al$$Ifl!vh5X 55p5$ #vX #v#vp#v$ :V l t06,5X 55p5$ al$$Ifl!vh5$#v$:V l t065$al$$Ifl!vh5X 55p5$ #vX #v#vp#v$ :V l t06,5X 55p5$ al$$Ifl!vh5X 55p5$ #vX #v#vp#v$ :V l t06,5X 55p5$ al$$Ifl!vh5X 55p5$ #vX #v#vp#v$ :V l t06,5X 55p5$ al$$Ifl!vh5X 55p5$ #vX #v#vp#v$ :V l t06,5X 55p5$ al$$Ifl!vh5X 55p5$ #vX #v#vp#v$ :V l t06,5X 55p5$ al$$Ifl!vh5X 55p5$ #vX #v#vp#v$ :V lx t06,5X 55p5$ al$$Ifl!vh5X 55p5$ #vX #v#vp#v$ :V l t06,5X 55p5$ al$$Ifl!vh5$#v$:V l t065$/ al$$Ifl!vh5X 55p5$ #vX #v#vp#v$ :V l t06,5X 55p5$ alp $$Ifl!vh5X 55p5$ #vX #v#vp#v$ :V l t06,5X 55p5$ alp $$Ifl!vh5X 55p5$ #vX #v#vp#v$ :V l t06,5X 55p5$ al$$Ifl!vh5X 55p5$ #vX #v#vp#v$ :V l t06,5X 55p5$ al$$Ifl!vh5X 55p5$ #vX #v#vp#v$ :V l t06,5X 55p5$ al$$Ifl!vh5$#v$:V l t065$/ al$$Ifl!vh5X 55p5$ #vX #v#vp#v$ :V l t06,5X 55p5$ alp $$Ifl!vh5X 55p5$ #vX #v#vp#v$ :V l t06,5X 55p5$ alp $$Ifl!vh5$#v$:V l t065$al$$Ifl!vh5X 55p5$ #vX #v#vp#v$ :V l t06,5X 55p5$ al$$Ifl!vh5$#v$:V l  t 065$alp $$Ifl!vh5X 55p5$ #vX #v#vp#v$ :V l t065X 55p5$ al$$Ifl!vh5$#v$:V l t065$al$$Ifl!vh5X 55p5$ #vX #v#vp#v$ :V l t065X 55p5$ al$$Ifl!vh5X 55p5$ #vX #v#vp#v$ :V l t065X 55p5$ al$$Ifl!vh5X 55p5$ #vX #v#vp#v$ :V l t065X 55p5$ al$$Ifl!vh5X 55p5$ #vX #v#vp#v$ :V l t065X 55p5$ al$$Ifl!vh5X 55p5$ #vX #v#vp#v$ :V l t065X 55p5$ alLDd (50  # A"}K0f-3'I)YK*@=QK0f-3'I)ތWmx[cKx |=D\W9nUJKQG]9\:UG$h_ZGI(UhJݾ6A*>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~NuMRoot Entry FڑData vWordDocument d*ObjectPoolZڑڑ_1240088015FZڑpYkڑOle EPRINTCompObjq  FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69q ՜.+,D՜.+,H@HP\h t          !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstLxyz{|}~lUkLLe EMFx@F, EMF+@xxFEMF+0@?@ @ @k@<0N?@<0}CQ{C}CCDBCDB; C@!b $$==_888% % W,G$S__"% % $$AA( F\PEMF+@<0吝BRCDBQCBRC吝BRC@$$=='%  % V,C0O= 5  %  % $$AAF4(EMF+ @$*8CFCCB( $$=='% % V00  a ""a a % % $$AAFEMF+@<0N?@H<*8CQC DQC DFC*8CFC*8CQC@$$==_888% % V02 ""a a % % $$AA( FEMF+*@$@B@B*8CFC@0$9=ARIAL6@\P7Piperacillin / Tazobactam AND Tobramycin AND Vancomycin=UU>r>UU>x<>UU>r>UU>>UU>ö>UU>g>UU> >UU>q?UU> ?UU>?UU>š?UU>,?UU>3?UU>;?UU>C?UU>U?UU>d?UU>!s?UU>@?UU>?UU>ْ?UU>š?UU>?UU>h?UU>U ?UU>?UU>8F?UU>?UU>?UU>p?UU>pt?UU>p$?UU>p?UU>T]?UU>#@UU>u@UU>9j @UU>^@UU>rX@UU>r@UU>9@UU>@UU>!@UU>:'@UU> )@UU>:-@UU>1@UU>6@UU> :@UU>c>@UU>ɵD@UU>;H@UU>L@UU>tN@UU>??   RpArialMonotype:Arial Bold:Versi?!333333000`,`䰞?>١?>Vͥ?>:?>r?>[?>tD?>8?>`?>X}?>Y?><?> ?>?>?>?>X@>@>l @>??   ( RpArialMonotype:Arial Regular:VerialMonotype:Arial ld:Versi?!333330K|p|m|Z|m| Fo3 0wLLH-3 ]13|p|m|-wo3!_|-w 0w Fdv% T:m۶Am۶A:LxAlternative regimens:tt % FEMF++@ *@$@B@B*8CFC6@xl:Piperacillin / Tazobactam AND Ciprofloxacin AND VancomycinUU>33>8b>33>{>33>c>33>>33>>33>q>33>?33>X ?33>?33>q?33>8N?33>/?33>7?33>7>?33>SF?33>S5X?33>h?33>?v?33>?33>?33>ڒ?33>?33>?33>ӥ?33>s?33>?33>s?33>a?33>?33>?33>?33>?33>?33>:?33>?33>?33>Y@33>:N@33>s@33> @33>_@33>@33>@33>@33>@33> @33>X%@33>'@33>X,@33>ʑ0@33><4@33>u8@33><@33>YA@33>E@33>I@33>=J@33>??   % Tm۶Am۶A:LPiperacillin / Tazobactam AND Ciprofloxacin AND Vancomycin     % FEMF++@ *@$@B@B*8CFC6@PD6Vancomycin AND Ciprofloxacin AND Tobramycin AND Flagyl89> ?9> ?1> ?U> ?G> ?> ?? ?$? ?3? ?j9? ?rr\L?>CT?>e?>Uuu?>C?>r,?>V?>?>r?>?>?>?>?>z?>8n?>8?>?>#?>?>?>rl?>VU?>?>?>P@>I@>p @>j @> @>@>@>Vu@>V@> @>%@>sl+@>`/@>WU3@>O5@>??   ( RpArialMonotype:Arial Bold:Versi?!33333300 |p|m|Z|m| Go3 0wPɁ3`H-3X|p|m|-wo3!_|-w 0w Gdv% T<bpm۶Am۶An(LPiperacillin / Tazobactam +/- Vancomycin  % FxlEMF++@ *@$@B@BQ_ChUWD@0$9=ARIAL6@Alternative Regimens:p?>r?>V?>?>?>:?>?>?>s?>t?>?>ʡ?>X?>?>?>:@>j@>W @>K @>@@>;@>??   ( RpArialMonotype:Arial Regular:VerialMonotype:Arial ld:Versi?!333330K|p|m|Z|m| Ho3 0wLLH-3x ]13|p|m|-wo3!_|-w 0w Hdv% Tqpm۶Am۶A}LxAlternative Regimens:L.  % FEMF++@ *@$@B@BQ_ChUWD6@`TClindamycin AND Ciprofloxacin $?UU>V8?UU>>?UU>8E?UU> U?UU>rd?UU>9t?UU>0?UU>rL?UU>h?UU>ȑ?UU>z?UU>:n?UU>?UU>0?UU>Vu?UU>h?UU>9?UU>?UU>?UU>s|?UU>We?UU>X?UU>Ɂ?UU>j?UU>?UU>@UU>:F@UU>@UU> @UU>??   % T`m۶Am۶ALClindamycin AND Ciprofloxacin    % FEMF++@ *@$@B@BQ_ChUWD6@+/- Vancomycin @UU>@UU>@UU>H@UU>A@UU>@UU>r @UU>$@UU>w(@UU>k,@UU>X2@UU>:5@UU>st9@UU>;@UU>??   % Tcm۶Am۶AcLh+/- Vancomycin % FthEMF++@ @H<ՋA 5BDBe@C 5BDBDݭBՋA 5B@$$==%  % V0W: o%  % $$AAF\PEMF+@<0N?@$$==_888% % V0Y: o% % $$AA( FEMF+*@$@B@BfA"`A@0$9=ARIAL6@|pSuspectr]>}>>}>#>}>U>}>8>}>9?}>'?}>??   % Tx3^,m۶Am۶A3*L\Suspect% FEMF++@ *@$@B@BfA"`A6@ Infection?3>33>VS>33>9n>33>r<>33>>33>Q>33> >33>>33>?33>U?33>??   % T.,a:m۶Am۶A.8 L`Infection?% FEMF++@ @;CD1B]^CD1BgCE1BoCcBoC 5BoCBgCeA]^CeA]^CeA]^CeA]^CeA]^CeA;CeA 2CeAF*CBF*C 5BF*CcB 2CB1B;CD1B@$$==%  ; "6 "X@ "    Y$  X4!    ! " "=<>C % $$AAF\PEMF+@<0N?@$$==_888% % ; "6 "X@ "    Y$  X4!    ! " "=<@E% % $$AA( FEMF+*@$@B@BF*CeA@0$9=ARIAL6@THENDG>""b>>""b>>""b>??   % T`%3m۶Am۶A1LTENDL. % FEMF++@ @<0N?@, C 5Bv: C 5B@$$==_888% % W$~+0  % % $$AA( F\PEMF+@<0CHBF*C 5BCLBCHB@( $$=='%  % V,'3 y  0 y%  % $$AAF4(EMF+ @$5 CR BAP:A( $$=='% % V0#67V V 77% % $$AAFEMF+*@$@B@B$B>mA@0$9=ARIAL6@H<NoS>I>>I>??   % TX%3m۶Am۶A1LPNo % F@4EMF++@ @$e@DQB C&B$$==% % V0y::6 6 :% % $$AAFEMF+@<0N?@H<e@T#C~CT#C~CDQBe@DQBe@T#C@$$==_888% % V0w:6 6 ::6 % % $$AA( Fl`EMF+*@$@B@Be@DQB@0$9=ARIAL6@See  Fever Assessment=>=>#,>>jk>>>>Uu>>U5>>>>J>>w ?>?>?>/?>>?>AL?>\?>sLj?>Wx?>?>s?>W?>??   % Tm۶Am۶ALxSee  Fever Assessment\M % FEMF++@ *@$@B@Be@DQB6@ Guidelines >33>`>33>>33>S?33>U%?33>#?33>H*?33>0?33>ql@?33>8>P?33>w^?33>??   % T*im۶Am۶A* LdGuidelines Se % FEMF++@ @<0N?@, DBDݭBDB8B@$$==_888% % W$GUKro% % $$AA( F\PEMF+@<0吝BZBDBDQBBZB吝BZB@( $$=='%  % V,CnOz5%  % $$AAF4(EMF+ @$psBpּB AP:A( $$=='% % V0<^VqTT% % $$AAFEMF+*@$@B@B(B_B@0$9=ARIAL6@THYesj:>I>'>I>ʢ>I>??   % T`>`Rnm۶Am۶A>lLTYesme% FthEMF++@ @H<wAhCDB*8CM ChCDBQCwAhC@$$==%  % V0 %  % $$AAF\PEMF+@<0N?@$$==_888% % V0 % % $$AA( FEMF+*@$@B@B-A"RDC@0$9=ARIAL6@H<Is>.>Ǒ>.>??   % TXDLm۶Am۶ADLPIs% FEMF++@ *@$@B@B-A"RDC6@|ppatientr|>[> >[>>[>Ǒ>[>U5>[>rl?[>9>?[>??   % Tx7[m۶Am۶A7L\patient% F EMF++@ *@$@B@B-A"RDC6@hemodynamicallyri=>r=>U8>>9΋>>q>>U>>>>U?>g?>+?>j1?>??>UuO?>U?>\?>??   % Twm۶Am۶ALlhemodynamically  % FEMF++@ *@$@B@B-A"RDC6@ unstable?9{>r?*>r?9μ>r?@>r?9>r?X?r?*?r?r|?r?9N*?r???   % T.bm۶Am۶A. L`unstable?% FEMF++@ @<0N?@, DBT#CDBv.C@$$==_888% % W$GK6  % % $$AA( F\PEMF+@<0B,CDB*8C吝B,CB,C@( $$=='%  % V,CO5   5 %  % $$AAF|EMF+@<0N?@, M ChCv.ChC@$$==_888% % W$ % % $$AA( F\PEMF+@<0,C cC*8ChC,CrnC,C cC@$$==%  % V, 1   1%  % $$AAF4(EMF+ @$\CT^CAP:A( $$=='% % V0F F   F % % $$AAFEMF+*@$@B@BˬC3[C@0$9=ARIAL6@THYesj:>I>'>I>ʢ>I>??   % T`m۶Am۶ALTYes% F@4EMF++@ @$(|DSC@B&B$$==% % V0R %@ %,,@ %@ % % $$AAFEMF+@<0N?@H<(|D}C(D0D}C(D0DSC(|DSC(|D}C@$$==_888% % V0P %,,@ %@ %% % $$AA( FEMF+*@$@B@B(|DSC@0$9=ARIAL6@ See  Candidar$>>p>>>>G>>U>>>>9?>`?>1!?>1?>UU7?>'G?>??   % Tdm۶Am۶Ad LdSee  Candida % FEMF++@ *@$@B@B(|DSC6@ Guidelines @`>33>`>33>>33>>33>J>33>?33>H ?33>?33>ql ?33>8>0?33>w>?33>??   % Tjm۶Am۶Aj LdGuidelines % FEMF++@ @<0N?@,  DhCDhC@$$==_888% % W$-J"$% % $$AA( F\PEMF+@<0@D cC(|DhC@DrnC@D cC@( $$=='%  % V,FRh$1 %h$h$1%  % $$AAFEMF+@?DQCMDQCQDQCTDt{CTDhCTD֚UCQDFCMDFCMDFCMDFCMDFC?DFCS  % $$AAF\PEMF+@<0N?@$$==_888% % ;/6s3X@ h4/5/5/5Z h4a s3a s3a s3a s3a 6/a X4/a =.Z =.=.//=<@U% % $$AA( FD8EMF+*@$@B@B8DFC@0$9=ARIAL6@Tailor antibioticj>UU>F>UU>>UU>r>UU>`>UU>>UU>U>UU>>UU>g>UU>U?UU>q?UU>8>?UU>-?UU>a3?UU>3C?UU>K?UU>plQ?UU>??   % TDm۶Am۶ALpTailor antibiotic% FEMF++@ *@$@B@B8DFC6@therapy based on丐=>=>@'>>f>>U5>>إ>>q|>>8>>q>>?>ǁ?>&?>r6?>9^F?>UEN?>^?>??   % TIm۶Am۶ALltherapy based on% F4(EMF++@ *@$@B@B8DFC6@culture results and<=33>r=33>UU'>33>q@>33>8`>33>>33>DZ>33>UU>33>#>33>U>33>r\?33>V?33>g ?33>&?33>.?33>D?33>ǑT?33>cd?33>??   % TKm۶Am۶ALtculture results and% FEMF++@ *@$@B@B8DFC6@ sensitivities#]> ?> ?> ?J> ?q> ?_> ?? ?? ?!? ?s? ?Z$? ?q*? ?8~:? ???   % T:m۶Am۶A Lhsensitivities% FEMF++@ @<0N?@, (D0DhCo6DhC@$$==_888% % W$,-% % $$AA( F\PEMF+@<06D cC8DhC6DrnC6D cC@( $$=='%  % V,-1=.--1%  % $$AAFh\EMF+@H<ՋAQCDBQCCQCDBQCՋAQC@( $$=='%  % V0<] ]]%  % $$AAF\PEMF+@<0N?@$$==_888% % V0:] ]]% % $$AA( FEMF+*@$@B@BfAEC@0$9=ARIAL6@ Sufficient@>9>G>9>>9>丵>9>>9>*>9>r>9>@>9>q ?9>C?9>??   % T0Oa]m۶Am۶A0[ L`Sufficient% FEMF++@ *@$@B@BfAEC6@ evidence ofDZ>>F>>q>>Ǒ>>U5>>>>q|>>?>?>?>Ɓ+?>??   % T)^hlm۶Am۶A)j Ldevidence of% FEMF++@ *@$@B@BfAEC6@ infection?#7>UU>jP>UU>؇>UU>>UU>J>UU>q>UU>>UU>8.>UU>?UU>?UU>??   % T/lbzm۶Am۶A/x L`infection?% FEMF++@ @<0N?@, DBQCDB; C@$$==_888% % W$GK5"% % $$AA( F\PEMF+@<0吝BRCDBQCBRC吝BRC@( $$=='%  % V,C0O= 5  %  % $$AAF4(EMF+ @$l~BqCAP:A( $$=='% % V0? S3-(-(% % $$AAFEMF+*@$@B@B(BœC@0$9=ARIAL6@H<NoS>I>>I>??   % TXA"O0m۶Am۶AA.LPNo % F@4EMF++@ @$*8CQ{C C&B$$==% % V0QD{  22 % % $$AAFEMF+@<0N?@H<*8CQQCQCQQCQCQ{C*8CQ{C*8CQQC@$$==_888% % V0OF} 22  % % $$AA( FthEMF+*@$@B@B*8CQ{C@0$9=ARIAL6@Await final results ofr>>R>>U>>㸱>>q\>>*>>>>>>j>> ?>?>*#?>+?>4?>q\D?>UR?>gb?>h?>p?>~?>`?>H?>??   % TV3dm۶Am۶AbLxAwait final results of % F(EMF++@ *@$@B@B*8CQ{C6@diagnostic work-upDZ%>33>d>33>?~>33>Þ>33>g>33> >33>8>33> ?33>?33>H?33>ǁ)?33>h1?33>E?33>UU?33>9>_?33>wm?33>v?33>`?33>??   % Te/sm۶Am۶AqLpdiagnostic work-up % FEMF++@ @<0N?@, CQCv.CQC@$$==_888% % W$~ch ] ]% % $$AA( F\PEMF+@<0,CiC*8CQC,C9ŵC,CiC@( $$=='%  % V,`l  ]  %  % $$AAF4(EMF+ @$5CCAP:A( $$=='% % V0\n0 0 ^ ^ 0 % % $$AAFEMF+*@$@B@BBC@0$9=ARIAL6@H<NoS>I>>I>??   % TX^lm۶Am۶AjLPNo % FthEMF++@ @H<wAhG^DDBRDM ChG^DDBnjDwAhG^D@$$==%  % V0H747:7%  % $$AAF\PEMF+@<0N?@$$==_888% % V0F747:7% % $$AA( FEMF+*@$@B@B-A)UD@0$9=ARIAL6@|pSuspectr>UU%>9>UU%>DZ>UU%>#>UU%> ?UU%>U?UU%>9'?UU%>??   % Tx3[^im۶Am۶A3gL\Suspect% FEMF++@ *@$@B@B-A)UD6@pdsevere>>U>>>> >> ?>P?>??   % Tp7iZwm۶Am۶A7uLXsevere% F EMF++@ *@$@B@B-A)UD6@intra-abdominalUU=33>>33>8B>33>Ua>33>r܃>33>>33>q>33>U>33>>33>9 ?33>?33>12?33>8?33>UUH?33>'X?33>??   % Txrm۶Am۶ALlintra-abdominal % FEMF++@ *@$@B@B-A)UD6@ infection?@~>?Ë>?g>?U5>?>?J>?q??8 ????Ɓ)????   % T/bm۶Am۶A/ L`infection?% FthEMF++@ @H<ՋAf~DDBsDCf~DDBhDՋAf~D@$$==%  % V0$?< ?5B?%  % $$AAF\PEMF+@<0N?@$$==_888% % V0&?< ?5B?% % $$AA( FEMF+*@$@B@BfAhvD@0$9=ARIAL6@ Suspect UTI?9=>>>1]>> >>9>>Q>>>>Ǒ>>0?>?>)?>1?>??   % T$lm۶Am۶A$ LdSuspect UTI? % FEMF++@ @<0N?@, DBnjDDBxqD@$$==_888% % W$GK:_<% % $$AA( F\PEMF+@<0吝BqDDBsDBqD吝BqD@( $$=='%  % V,COH<<5H<H<%  % $$AAF4(EMF+ @$l~BlDA`:A( $$=='% % V0?S0;N<(N<(0;0;% % $$AAFEMF+*@$@B@B(BkD@0$9=ARIAL6@H<NoS>I>>I>??   % TXAOm۶Am۶AALPNo % FEMF++@ @<0N?@, DBhDDB~D@$$==_888% % W$G!K>5BC% % $$AA( F\PEMF+@<0吝BPDDBDBPD吝BPD@( $$=='%  % V,C:OGCaD5CC%  % $$AAF4(EMF+ @$l~BgXDA@:A( $$=='% % V0?*S=BC(C(BB% % $$AAFEMF+*@$@B@B(BD@0$9=ARIAL6@H<NoS>I>>I>??   % TXA,O:m۶Am۶AA8LPNo % FEMF++@ @ATDDCBTDCTD~CD~CD~C׸DCDICBDHCBDHCBDHCBDDCBDAD5ADe@ָDe@D\e@D5ASDATD@$$==%  ;PF6FX@ lFFvEDlaDaDaDaDaDY$aDPaDX4aD:D:vE:FFPF=<>Fi % $$AAF\PEMF+@<0N?@$$==_888% % ;PF6FX@ lFFvEDlaDaDaDaDaDY$aDPaDX4aD:D:vE:FFPF=<@Dk% % $$AA( F`TEMF+*@$@B@Be@D@0$9=ARIAL6@Look for alternative*>=q[>=r\>=>=q>=@>=9>=X?= ?=?=%?=r+?=3?=UC?=9M?=\?=DZl?=t?=z?=Ǒ?=??   % TH{Vm۶Am۶ATLtLook for alternative% FEMF++@ *@$@B@Be@D6@xetiologyU>33>>33>?33>U ?33>?33>(#?33>2?33>qB?33>??   % T|4V]dm۶Am۶A4bL\etiology% F@4EMF++@ @$Q_C(1yDiC&B$$==% % V0lM>@/@/M>M>% % $$AAFEMF+@<0N?@H<Q_C΁D?D΁D?D(1yDQ_C(1yDQ_C΁D@$$==_888% % V0j@/@/M>M>@% % $$AA( FEMF+*@$@B@BQ_C(1yD@0$9=ARIAL6@ TobramycinDZ?""b>a?""b>?""b>?""b>J?""b>3?""b>?""b>?""b>V@""b>@""b>??   ( RpArialMonotype:Arial Bold:Versi?!33333300 $|p|m|Z|m| Io3 0wLH-3ӧ|p|m|-wo3!_|-w 0w Idv% TXm۶Am۶A L`Tobramycin % FEMF++@ @<0N?@, Cf~D;YCf~D@$$==_888% % W$~e ?,?% % $$AA( F\PEMF+@<0C4|DQ_Cf~DCDC4|D@( $$=='%  % V,am>???>?%  % $$AAF4(EMF+ @$0~jCU{D A`:A( $$=='% % V0>@.@.>>% % $$AAFEMF+*@$@B@BiWCj{D@0$9=ARIAL6@THYesj:>I>'>I>ʢ>I>??   ( RpArialMonotype:Arial Regular:Ve?!33333300 0`|Ȅ,`ȄG4`G |p|m|Z|m| Jo3 0wLTH-3|p|m|-wo3!_|-w 0w Jdv% T`m۶Am۶ALTYes% FEMF++@ @<0N?@4(?Df~DFDf~DFDgNJC@$$==_888% % W(/?1?1Y% % $$AA( F\PEMF+@<04gED!CFDQCFHD!C4gED!C@( $$=='%  % V, "Z1p12pZ1p%  % $$AAF|EMF+@<0N?@, M ChG^D;YChG^D@$$==_888% % W$we|7,7% % $$AA( F\PEMF+@<0C\DQ_ChG^DCܶ_DC\D@$$==%  % V,asm677767%  % $$AAF4(EMF+ @$OlC[D(A@:A( $$=='% % V0o68T8T66% % $$AAFEMF+*@$@B@B$ZC*ZD@0$9=ARIAL6@THYesj:>I>'>I>ʢ>I>??   % T`qm۶Am۶A}LTYes% FEMF++@ @<0N?@4(?DhG^DFDhG^DFDgNJC@$$==_888% % W(|/7171Y% % $$AA( F\PEMF+@<04gED!CFDQCFHD!C4gED!C@( $$=='%  % V, "Z1p12pZ1p%  % $$AAFh\EMF+@H<*8CQhCoCQCQCQhCoC(D*8CQhC@( $$=='%  % V0(  .u. .%  % $$AAF\PEMF+@<0N?@$$==_888% % V0* .u. .% % $$AA( FEMF+*@$@B@BMmACC@0$9=ARIAL6@ Gram stainx>}>l>}>9n>}>>}>Uu>}>C>}>Z?}>A ?}>?}>Ue ?}>??   % T m۶Am۶A L`Gram stain  % FEMF++@ *@$@B@BMmACC6@ available?x*>33>i>33>Q>33>U>33>㘽>33>q<>33>>33>?33> ?33>U?33>??   % T m۶Am۶A L`available?% FthEMF++@ @H<T#C DoCDQC DoC.DT#C D@$$==%  % V0K=6 )($)(+6 )(%  % $$AAF\PEMF+@<0N?@$$==_888% % V0I?6 )($)(+6 )(% % $$AA( FEMF+*@$@B@BM0C8D@0$9=ARIAL6@|p2 blood>UUU>>UUU>Uu>UUU>r ?UUU>9?UUU>!?UUU>ǁ1?UUU>??   % Txdrm۶Am۶ApL\2 blood% F EMF++@ *@$@B@BM0C8D6@cultures positive2>>k>>x>>q>>>>8>>>>?>J?>1?>(?>U7?>9F?>`L?>GT?>Z?>h?>??   % Tsm۶Am۶ALpcultures positive% F EMF++@ *@$@B@BM0C8D6@OR sputum cultureU=33>H>33>>33>X>33>ʹ>33>8n>33>>33>o?33>A?33>+?33>3?33>B?33>TQ?33>7X?33>7`?33>o?33>hy?33>??   % T m۶Am۶ALpOR sputum culture  % FEMF++@ *@$@B@BM0C8D6@ positive?>?U>?X>?Ue????8????(+??:????   % Tm۶Am۶A L`positive?% FEMF++@ @<0N?@, oC(DoC<D@$$==_888% % W$ C $% % $$AA( F\PEMF+@<0rxuCDoCDiCDrxuCD@( $$=='%  % V,?KX#$#X#%  % $$AAF4(EMF+ @$0cCvD A@:A( $$=='% % V0!49"9=#=#"9"% % $$AAFEMF+*@$@B@BiPCD@0$9=ARIAL6@THYesj:>I>'>I>ʢ>I>??   % T`#1m۶Am۶A/LTYes% FthEMF++@ @H<*8C(HDoC((>DQC(HDoC(RD*8C(HD@$$==%  % V0(L %2/u%24 %2%  % $$AAF\PEMF+@<0N?@$$==_888% % V0*N %2/u%24 %2% % $$AA( FEMF+*@$@B@BMmAC@D@0$9=ARIAL6@pd1 of 2*>=9έ>=r>=@>=9>=r>=??   % Tpm۶Am۶ALX1 of 2% FEMF++@ *@$@B@BMmAC@D6@xculturesxc>}>9.>}>ѭ>}>Uu>}>C>}>>}>>}>9>?}>??   % T|!m۶Am۶AL\cultures% FEMF++@ *@$@B@BMmAC@D6@ positive forU>33>qV>33>>33>>33>'>33>U>33>>33> >33>W?33>8>?33>T%?33>%?33>??   % T! /m۶Am۶A- Ldpositive for% FEMF++@ *@$@B@BMmAC@D6@\PGNR?9N>?9>?>?r\????   % Td0>m۶Am۶A<LTGNR? % FEMF++@ @<0N?@, oC.DoC;D@$$==_888% % W$+.% % $$AA( F\PEMF+@<0rxuC@I;DoC((>DiC@I;DrxuC@I;D@( $$=='%  % V,X./.X.%  % $$AAF4(EMF+ @$5KfC3DA@:A( $$=='% % V0e,e..,e,% % $$AAFEMF+*@$@B@BiPC2D@0$9=ARIAL6@H<NoS>I>>I>??   % TXm۶Am۶ALPNo % FEMF++@ @<0N?@4(*8C(HDDB(HDDBݜOD@$$==_888% % W(G A %2%23% % $$AA( F\PEMF+@<0吝BAODDBRDBAOD吝BAOD@( $$=='%  % V,C=OI34533%  % $$AAF4(EMF+ @$3BFDA@:A( $$=='% % V0ey+Z1Z221Z1% % $$AAFEMF+*@$@B@BNVB-ED@0$9=ARIAL6@H<NoS>I>>I>??   % TXgu(m۶Am۶Ag&LPNo % FEMF++@ @<0N?@, QC(HD;YC(HD@$$==_888% % W$% e%u%2,%2% % $$AA( F\PEMF+@<0C#GDQ_C(HDCJDC#GD@( $$=='%  % V,am)1%221%  % $$AAF4(EMF+ @$CFD A@:A( $$=='% % V0=W+12d2d11% % $$AAFEMF+*@$@B@B4C-ED@0$9=ARIAL6@THYesj:>I>'>I>ʢ>I>??   % T`?S(m۶Am۶A?&LTYes% FEMF++@ @<0N?@4(?D(HDFD(HDFDgNJC@$$==_888% % W(%/%21%21Y% % $$AA( F\PEMF+@<04gED!CFDQCFHD!C4gED!C@( $$=='%  % V, "Z1p12pZ1p%  % $$AAF4(EMF+ @$Q_CTDiCxBC( $$=='% % V0l!"=./=./""% % $$AAFEMF+@<0N?@H<Q_C8D?D8D?DTDQ_CTDQ_C8D@$$==_888% % V0j=./=./""=.% % $$AA( FEMF+*@$@B@BQ_CTD@0$9=ARIAL6@ Gram (+):9=www>U>www>qZ>www>q>www>@>www>1>www>j>www>r\>www>??   % Tp0>m۶Am۶Ap< L`Gram (+):  % FEMF++@ *@$@B@BQ_CTD@0$9=ARIAL6@Cefazolin OR Vancomycin9?www>?www>r?www>x?www>a?www>:~?www>:.?www>!?www>V?www>b@www>r\@www>r@www>@www>@www>@www>@www> @www>!@www>X%@www>+@www>/@www>3@www>W5@www>??   ( RpArialMonotype:Arial Bold:Versi?!33333300 R|p|m|Z|m| Ko3 0wLH-3]1|p|m|-wo3!_|-w 0w Kdv% T0>m۶Am۶A<L|Cefazolin OR Vancomycin   % FEMF++@ *@$@B@BQ_CTD@0$9=ARIAL6@ Gram (-):9<""?=""?U>""?qZ>""?q>""?@>""?1>""?#>""?U>""???   ( RpArialMonotype:Arial Regular:VerialMonotype:Arial ld:Versi?!333330!|p|m|Z|m| Lo3 0wLH-3]1|p|m|-wo3!_|-w 0w Ldv% TpN\m۶Am۶ApZ L`Gram (-):  % FEMF++@ *@$@B@BQ_CTD@0$9=ARIAL6@8,Piperacillin / Tazobactam 9?""? ?""?9?""?9?""??""? ?""??""??""?W?""?ؾ?""?s?""??""?p?""?c?""?W?""?J?""??""??""??""??""?0@""?r$@""? @""?w @""?k@""?:@""???   ( RpArialMonotype:Arial Bold:VersirialMonotype:Arial gular:VerialMonype:Arial \|p|m|Z|m| Mo3 0wLH-3]1|p|m|-wo3!_|-w 0w Mdv% TNr\m۶Am۶AZLPiperacillin / Tazobactam  % FEMF++@ *@$@B@BQ_CTD6@AND Tobramycin@""?@""?V"@""? (@""?*@""?q.@""?2@""?!7@""?:9@""?=@""?W-D@""?!H@""?;L@""?N@""???   % TvN\m۶Am۶AvZLhAND Tobramycin  % FEMF++@ *@$@B@BQ_CTD@0$9=ARIAL6@`T Alternative regimens:9?DD$?ǁ?DD$?Uu?DD$?h?DD$?q\?DD$?O?DD$?C?DD$?7?DD$?*?DD$?7?DD$??DD$?ó?DD$??DD$??DD$?q\?DD$?UE?DD$?9.?DD$?!?DD$?J?DD$?g?DD$?P?DD$?C?DD$??DD$??DD$?h@DD$?V@DD$?@DD$?: @DD$?@DD$?`@DD$???   ( RpArialMonotype:Arial Regular:VerialMonotype:Arial ld:VersirialMonype:Arial j|p|m|Z|m| No3 0wLHH-3]1|p|m|-wo3!_|-w 0w Ndv% T]kkm۶Am۶AiL Alternative regimens: % FpdEMF++@ *@$@B@BQ_CTD6@0$Piperacillin / Tazobactam9?ffF? ?ffF?3?ffF?s?ffF?W?ffF??ffF??ffF?dz?ffF??ffF??ffF?A?ffF?j?ffF?S?ffF?!G?ffF?:?ffF?=.?ffF?=?ffF?!?ffF??ffF?w?ffF?[?ffF?@ffF?X]@ffF?W@ffF?K @ffF???   % Tkhym۶Am۶AwLPiperacillin / Tazobactam% FEMF++@ *@$@B@BQ_CTD@0$9=ARIAL6@@4 8@ffF???FXLEMF++@ *@$@B@BQ_CTD@0$9=ARIAL6@ AND Ciprofloxacin1@ffF?+@ffF?@ffF?r @ffF?/$@ffF?(&@ffF?K+@ffF?,@ffF?s0@ffF?23@ffF?'7@ffF? 9@ffF?W:@ffF?ɩ>@ffF?8B@ffF?t,F@ffF?I@ffF?OK@ffF???   % Tlkym۶Am۶AlwLp AND Ciprofloxacin  % FEMF++@ *@$@B@BQ_CTD6@L@Ciprofloxacin AND Tobramycin9?h?Ӎ?h?r?h?V?h?ȡ?h??h?:~?h??h??h?t?h?X?h?ʱ?h??h??h? ?h?3?h?x?h?ff?cM>ff?UU>ff?>ff?ǵ>ff?>ff?>ff?9N ?ff???   % Tpm۶Am۶Ap L`Mixed Gram  % F4(EMF++@ *@$@B@BQ_CTD@0$9=ARIAL6@(Piperacillin / Tazobactam AND Tobramycin9?ff? ?ff?9?ff?9?ff??ff? ?ff??ff??ff?W?ff?ؾ?ff?s?ff??ff?p?ff?c?ff?W?ff?J?ff??ff??ff??ff??ff?0@ff?r$@ff? @ff?w @ff?k@ff?:@ff?@ff?@ff?W"@ff? (@ff?*@ff?q.@ff?2@ff?!7@ff?;9@ff?=@ff?X-D@ff?!H@ff?<L@ff?N@ff???   ( RpArialMonotype:Arial Bold:VersirialMonotype:Arial gular:VerialMonype:Arial $|p|m|Z|m| Oo3 0wPɁ3`H-3]1|p|m|-wo3!_|-w 0w Odv% T<m۶Am۶A(LPiperacillin / Tazobactam AND Tobramycin   % FEMF++@ *@$@B@BQ_CTD@0$9=ARIAL6@ (+) and (-)9ww?*>ww?GJ>ww?DŽ>ww?j>ww?9>ww?r>ww?9>ww?>ww???   ( RpArialMonotype:Arial Regular:VerialMonotype:Arial ld:VersirialMonype:Arial (|p|m|Z|m| Po3 0wL4H-3x ]13|p|m|-wo3!_|-w 0w Pdv% Tpm۶Am۶Ap Ld(+) and (-)% FEMF++@ *@$@B@BQ_CTD6@( Alternative regimens:9?ww?ǁ?ww?Uu?ww?h?ww?q\?ww?O?ww?C?ww?7?ww?*?ww?7?ww??ww?S?ww??ww?o?ww?ߺ?ww?Ӿ?ww??ww??ww?5?ww?á?ww?5?ww?G?ww?:?ww?#?ww??ww??ww?ű?ww?S?ww?g@ww?T@ww?@ww? @ww?A @ww?86@ww?*@ww?@ww?@ww? @ww?r$@ww?"(@ww???   % T<m۶Am۶A(L Alternative regimens: % F$EMF++@ *@$@B@BQ_CTD6@+Piperacillin / Tazobactam AND Ciprofloxacin9?? ??3??s??W??????dz??????A??j??S??!G??:??=.??=??!????w??[??@?X]@?W@?K @?8@?1@?@?@?Y5"@? /$@?Q)@?=*@?.@?81@?Z-5@?!'7@?8@?<@?>>@@?2D@?G@?[UI@???   % TPm۶Am۶A+LPiperacillin / Tazobactam AND Ciprofloxacin   % F$EMF++@ *@$@B@BQ_CTD6@+Vancomycin AND Ciprofloxacin AND Tobramycin9?? ????sܜ????????׾????u??Y????Yu????????s@?0@?W%@?@?x @?q@?;@?@?@?X}@? @? @?u$@?<&@?uL+@? o0@?ˑ5@?7@?;@??@?vC@?*F@?!J@? P@?̙S@?(W@?wX@???   % TPm۶Am۶A+LVancomycin AND Ciprofloxacin AND Tobramycin     % FEMF++@ @<0N?@, QC D;YC D@$$==_888% % W$:e)(,)(% % $$AA( F\PEMF+@<0C44DQ_C DC"DC44D@( $$=='%  % V,a|m')(('%  % $$AAF4(EMF+ @$ݣCU-D A@:A( $$=='% % V0Gxa|'|(('|'% % $$AAFEMF+*@$@B@B$Cj>D@0$9=ARIAL6@THYesj:>I>'>I>ʢ>I>??   % T`Iz]m۶Am۶AILTYes% FEMF++@ @<0N?@4(?D DFD DFDgNJC@$$==_888% % W(/)(1)(1Y% % $$AA( F\PEMF+@<04gED!CFDQCFHD!C4gED!C@( $$=='%  % V, "Z1p12pZ1p%  % $$AAF4(EMF+ @$Q_C?DiCB( $$=='% % V0lF/Q4/Q4///% % $$AAFEMF+@<0N?@H<Q_CAQD?DAQD?D?DQ_C?DQ_CAQD@$$==_888% % V0jGQ4/Q4///Q4% % $$AA( FEMF+*@$@B@BQ_C?D@0$9=ARIAL6@\P7Piperacillin / Tazobactam AND Tobramycin +/- Vancomycin >UU>>UU>>UU>>UU>C>UU>3 ?UU>U?UU>(?UU>80?UU>T8?UU>p@?UU>sH?UU>Y?UU>a?UU>ġi?UU>q?UU>pt?UU>T]?UU>y?UU>)?UU>١?UU>©?UU>?UU>h?UU>P?UU>9?UU>?UU>/?UU>qt?UU>ƹ?UU>T?UU>T]?UU>@UU>@UU>@UU> @UU>9@UU>@UU>@UU>@UU>$!@UU>#@UU>E'@UU>?)@UU>ǝ+@UU>-@UU>U2@UU>9J6@UU>9:@UU>>@UU>B@UU>VAI@UU>5M@UU>:*Q@UU>$S@UU>??   ( RpArialMonotype:Arial Bold:Versi?!33333300 B|p|m|Z|m| Qo3 0wx/3H-3D|p|m|-wo3!_|-w 0w Qdv% Tm۶Am۶A7LPiperacillin / Tazobactam AND Tobramycin +/- Vancomycin    % FxlEMF++@ *@$@B@BQ_C?D@0$9=ARIAL6@Alternative Regimens:p?>r?>V?>?>?>:?>?>?>s?>t?>?>ʡ?>X?>?>?>:@>j@>W @>K @>@@>;@>??   ( RpArialMonotype:Arial Regular:VerialMonotype:Arial ld:Versi?!333330K|p|m|Z|m| Ro3 0wLLH-3 ]13|p|m|-wo3!_|-w 0w Rdv% Tp!m۶Am۶ALxAlternative Regimens:  % FpdEMF++@ *@$@B@BQ_C?D6@0$Piperacillin / Tazobactam8?33>K?33>VER?33>b?33>q?33>a{?33>ș?33>:?33>ߏ?33>?33>0?33>Y?33>B?33><6?33>)?33>X?33>X͵?33>?33>?33>v?33>Z?33>̩?33>Z?33>>?33>??   % T!F/m۶Am۶A-LPiperacillin / Tazobactam% F(EMF++@ *@$@B@BQ_C?D6@ AND Ciprofloxacin_?33>R?33>g@33>9 @33>@33>@33>V@33>]@33>:R@33>s@33>!@33>#@33>3%@33>')@33>ɵ,@33>;0@33>t84@33>5@33>??   % TG!/m۶Am۶AG-Lp AND Ciprofloxacin  % FEMF++@ *@$@B@BQ_C?D6@L@Ciprofloxacin AND TobramycinȆ? ?9? ?7? ? ? ?sܠ? ?WŨ? ?帬? ?? ?ʷ? ?? ?? ?u? ?Y? ?=? ?? ?=n? ?? ?? ?u? ?:@ ?@ ? @ ?W@ ? @ ?;@ ?t@ ?@ ? @ ???   % T0>m۶Am۶A<LCiprofloxacin AND Tobramycin   % F@4EMF++@ @$Q_CQ CiCB$$==% % V0lY /Y /% % $$AAFEMF+@<0N?@H<Q_CbD?DbD?DQ CQ_CQ CQ_CbD@$$==_888% % V0jY /Y /Y % % $$AA( FEMF+*@$@B@BQ_CQ C@0$9=ARIAL6@\P7Piperacillin / Tazobactam AND Tobramycin +/- Vancomycin >UU>>UU>>UU>>UU>C>UU>3 ?UU>U?UU>(?UU>80?UU>T8?UU>p@?UU>sH?UU>Y?UU>a?UU>ġi?UU>q?UU>pt?UU>T]?UU>y?UU>)?UU>١?UU>©?UU>?UU>h?UU>P?UU>9?UU>?UU>/?UU>qt?UU>ƹ?UU>T?UU>T]?UU>@UU>@UU>@UU> @UU>9@UU>@UU>@UU>@UU>$!@UU>#@UU>E'@UU>?)@UU>ǝ+@UU>-@UU>U2@UU>9J6@UU>9:@UU>>@UU>B@UU>VAI@UU>5M@UU>:*Q@UU>$S@UU>??   ( RpArialMonotype:Arial Bold:Versi?!33333300 v|p|m|Z|m| So3 0wx/3H-3||p|m|-wo3!_|-w 0w Sdv% Tm۶Am۶A7LPiperacillin / Tazobactam AND Tobramycin +/- Vancomycin    % FxlEMF++@ *@$@B@BQ_CQ C@0$9=ARIAL6@Alternative regimens:r4?>䰮?>ٱ?>V͵?>:?>r?>[?>tD?>8?>`?>X}?>Y?><?> ?>t@>t@>@>X @>@>l@>??   ( RpArialMonotype:Arial Regular:VerialMonotype:Arial ld:Versi?!333330K|p|m|Z|m| To3 0wLLH-3 ]13|p|m|-wo3!_|-w 0w Tdv% Tmm۶Am۶ALxAlternative regimens: % F, EMF++@ *@$@B@BQ_CQ C6@,Piperacillin / Tazobactam AND Ciprofloxacin r<>33>9.>33>>33>Uu>33>r ?33>V?33>$?33>3?33>a9?33>??33>VF?33>WL?33>(\?33>d?33>k?33>8s?33>?33>?33>r?33>V?33>:v?33>_?33>{?33>o?33>X?33>0?33>t$?33>?33>;?33>+?33>?33>sd?33>W?33>@33>V@33> @33> @33> @33>s@33>@33>@33>W@33>5@33>;* @33>??   % TTm۶Am۶A,LPiperacillin / Tazobactam AND Ciprofloxacin    % FEMF++@ *@$@B@BQ_CQ C6@+/- Vancomycin$"@33>K&@33>D(@33>*@33>,@33>[1@33>O5@33>D9@33>9<@33>@@33>F@33>VAJ@33>M@33>dO@33>??   % Tm۶Am۶ALh+/- Vancomycin % FEMF++@ *@$@B@BQ_CQ C6@XLCiprofloxacin AND Tobramycin U5'? ?;? ?B? ?Q? ?r\[? ?9.k? ?Us? ?gy? ?r? ?下? ?ȡ? ?:? ?? ?Х? ?é? ?@? ?W? ?? ?:? ?:n? ?W? ?@? ?t? ?X? ?:@ ???   % Tbm۶Am۶AbLh+/- Vancomycin % FEMF++@ @<0N?@4(?DQhCFDQhCFDgNJC@$$==_888% % W(/.1.1Y% % $$AA( F\PEMF+@<04gED!CFDQCFHD!C4gED!C@( $$=='%  % V, "Z1p12pZ1p%  % $$AAF|EMF+@<0N?@, QCQhC;YCQhC@$$==_888% % W$%eu.,.% % $$AA( F\PEMF+@<0CiCQ_CQhCC9GCCiC@$$==%  % V,am.%  % $$AAF4(EMF+ @$JC{CAP:A( $$=='% % V0@T  88 % % $$AAFEMF+*@$@B@B4CԝC@0$9=ARIAL6@H<NoS>I>>I>??   % TXBPm۶Am۶ABLPNo % FEMF++@ @<0N?@, DBQCDB;C@$$==_888% % W$GK% % $$AA( F\PEMF+@<0吝B[CDBQCB[C吝B[C@( $$=='%  % V,COl$5ll%  % $$AAF4(EMF+ @$psBzC AP:A( $$=='% % V0<VpTTpp% % $$AAFEMF+*@$@B@B(BŜC@0$9=ARIAL6@THYesj:>I>'>I>ʢ>I>??   % T`>Rm۶Am۶A>LTYes% FthEMF++@ @H<e@QhCDBQC~CQhCDBDe@QhC@$$==%  % V0:.$.7!:.%  % $$AAF\PEMF+@<0N?@$$==_888% % V0:.$.7!:.% % $$AA( FEMF+*@$@B@BwrA-C@0$9=ARIAL6@|pSuspect>i>U>i>x>i>U?i>?i>"?i>0?i>??   % Tx3^m۶Am۶A3L\Suspect% FEMF++@ *@$@B@BwrA-C6@ pneumonia ORDZ>>U>>>>C>>>>J>>w ?>H?>"?>ql2?>S:?>sP?>??   % T rm۶Am۶A  Ldpneumonia OR  % FEMF++@ *@$@B@BwrA-C6@ bacteremia?G\>UU>Ǎ>UU>j>UU>q>UU>>UU>8N>UU> ?UU>?UU>-?UU>U3?UU>C?UU>??   % T'im۶Am۶A' Ldbacteremia? % FEMF++@ @<0N?@, DBDDBݜOD@$$==_888% % W$GKA7!3% % $$AA( F\PEMF+@<0吝BAODDBRDBAOD吝BAOD@( $$=='%  % V,C=OI34533%  % $$AAF4(EMF+ @$l~B)DA@:A( $$=='% % V0?SB*`+(`+(B*B*% % $$AAFEMF+*@$@B@B(B(D@0$9=ARIAL6@H<NoS>I>>I>??   % TXAOm۶Am۶AALPNo % FEMF++@ @<0N?@, ~CQhCv.CQhC@$$==_888% % W$. .% % $$AA( F\PEMF+@<0,CiC*8CQhC,C9GC,CiC@( $$=='%  % V,  .  %  % $$AAF4(EMF+ @$0&C{C AP:A( $$=='% % V0s s   s % % $$AAFEMF+*@$@B@BivCԝC@0$9=ARIAL6@THYesj:>I>'>I>ʢ>I>??   % T`m۶Am۶ALTYes% FEMF++@ @Q{CDmB2DDmB5DFmB8DB8DEݭB8DDݭB8DCݭB8DBݭB8D-B5DlB2DlBQ{ClBdϠClBQC-BQCBݭBPCBcϠCBmBP{CDmB@$$==%  ;,6,,X@ v-,=.e=.o=.o=.o=.o=.zv-,6X4SzSoSe,,=<>5;s % $$AAF\PEMF+@<0N?@$$==_888% % ;,6,,X@ v-,=.e=.o=.o=.o=.o=.zv-,6X4SzSoSe,,=<@39u% % $$AA( FEMF+*@$@B@BFC>{vB@0$9=ARIAL6@x;This algorithm is intended to apply to nosocomial-acquired33>.>3>.>3>.>l>.>$>.>y?.>`K?.>|2?.>|0?.>|A?.>CM?.>_T?.>Cd^?.>Co?.>w?.>{?.>n?.>wW?.>K?.>>?.>?.>?.>铱?.>C?.>?.>?.>͌?.>[?.>?.>[?.>??.>?y?.>@.>g@.>@.>@.>g @.>T @.>@.>g@.>g@.>gV@.>J @.>٢$@.>K(@.>K,@.>A3@.>;5@.>/09@.>);@.>/=@.>|A@.>qE@.>I@.>!N@.>P@.>LR@.>V@.>??   ( RpArialMonotype:Arial Bold:Versi???!33333300 o|p|m|Z|m| Uo3 0wɂ3tH-3l|p|m|-wo3!_|-w 0w Udv% T]@Nm۶Am۶A]L;LThis algorithm is intended to apply to nosocomial-acquired  % FEMF++@ *@$@B@BFC>{vB6@?infections. See accompanying text for discussion of community-.>[>t">[>g>[>>[>>[>33>[>$>[>3>[>?[>9?[>a '?[>}.?[>6?[>>?[>Q?[>`a?[>']q?[>CDy?[>?[>s?[>\?[> ?[>"?[>"b?[>K?[>?[>?[>x?[>x?[>x7?[>+?[>x?[>\?[>@?[>u?[>@[>@[>j@[>K/ @[>) @[>@[>z@[>Ko@[>c@[>@[>/"@[>&@[>h(@[>h,@[>hN1@[>/H3@[>/7@[>h9@[>/;@[>?@[>DD@[>LJ@[>P@[>AU@[>Y@[>[@[>]@[>ia@[>??   % TMO]m۶Am۶AM[?Linfections. See accompanying text for discussion of community-  % FEMF++@ *@$@B@BFC>{vB6@>acquired infections commonly encountered in surgical patients.m">>a>>}>>=>>>>>>>> ?>)?>'?>.?>W@?>I?>}Y?>Dti?>(r?>Dz?>"?>"ʎ?>?>?>x?>x??>?>"?>":?>"?>?>?>"?>?>S?>;?>u@>@>% @>.@>x@>=@>1@>@>K@>}!@>%@>'@>K+@>K0@>2@>77@>19@>%=@>hA@>/C@> E@>eI@>hZM@>O@>hQ@>ڦU@>Y@>]\@>Q`@>??   % TQ]km۶Am۶AQi>Lacquired infections commonly encountered in surgical patients. % FEMF++@ LdTjSi)??" FEMF+@ ObjInfo VisioDocumentwVisioInformation" SummaryInformation( dVisio (TM) Drawing b]Rd !fffMMM3338 TZ Arial@:LJ"X NDZTimes New RoWman@N}WingdUs@NMonotype_ Sort Symbol5T?? Y@-1U,J:DT1EW-h LT4* %U_b  0{Gz?R@&$6YEWb ooeoY ! k'(no RYY=,=,>p/&'$? AY&| ,,'#/5%&PF$&p o 3& y pnp)pL?^2 o o oooo*ooo廀?aBEEEEEEL@<`pBEUEEEEUEE@sO'FAkY;AVVA~AY??I\#25l =,=,=,#Ѓ}+cQb6W#Q Q Q iP| 'onW'07U> Y??4;jg2G#:}{ { J{ { { 0Rkjb#/L!3_۶۶D//b/@Q`_?*dۼ۷4 Ak@YUo%1߅-(Yp @ٻ !-0N`#ew)///ϡ/?2S9ϭ]op|7%nߤ$ -?Qcuw#U2qa?`r/ir b / "%)FX kU TY/}b /,>:/L/^/p//c'S@T#d:QGBT'a58R \RR_A_Ayb8Q8Qb\Q\QrQQْ+Q+Q ˑFqqFّّs AA@QBAFAARssFոF#Q#QFQQ@F=Q=QoIRJQFDWQWQFdQdQF ool}R~QFыQ"QFјQQFll1RQ벿QQ"@FQQ#21$T!RQ&#nA b ah"!)F'a*'a*FB]d+Fba[?m?????????O!O%BO$bAuoooooooo);"dU(`q} 1DC"-d!`̱͏ߏ@'9K"\k"`ß՟ /ADS"Šn'A˯ݯ@%7I[",|!Aӿ -?QLcϏ"\LAϷ#5GYkߏ"ߘ'Q+=Oas"',Q!3E!oC.hH 1 *PrCp&quC1);MWi{"fQ+=Oas_q E##Q/!/3/E/W/i/{/$0' `Q?#?5?G?Y?k?}?????? ?( mQO+O=OOOaOsOOOOOODO 5O" _0_B_T_f_x_______Ju ? &o8oJo\onoooooooDoe".@Rdv@ E" 9K]oɏۏLO>PbtΟMSMM"'FXj|į֯p M-$N`r̿޿///QOǁNk#6/VhzϞϰ .*DVכh.ߞ߰ .@R.ָQtPݣ. .@Rdv. Rd  .@Rdv [g& +n5EWi$2qO0?pN?`68? M A2U'i#&D$q!(=59'2rX26j$??((Sx7x4rO!3B0%FR9e%!n/////////?"?4?F?_UwJ?8&A?vP[t??L?&w*OOOO _0b_t_y?CDNjƌƇ/______*+s8m̑!+.7?I?_ 3BarkGs!?Up\#>LlߣHb3sqUA1DbWrq>ia*BK>OoUoi .4RSBa wh|  odhh5GY lne hCanon BJC-4300]o" 4!*@@'j d\3.@Rd} DisplayUFDf hZRTUU4UmA@ ?I?d Hx4 4 4bZb))ueqYk[UHBo4š-!"-!4` Flowchartc`l[bck[bc&{&j[%& !N" T*u D??!?T pNsNp_imƉp}wv|lcY?>This symbol represents a decision or switching type fu7nct.HD '# =ih0>T@dE=7]AUAZ@ ?]?P} 4 ^4bj$4u7k` =uHBA" >zo7jp"zz > 4UAA3!0%D >D2%RZEQD %RZU?r-# )In~"~4#"~LR*{#a1f41;C/`9Copyright 1997 Visio Corporation. All 2s reserved.4`Shape.hlp!#18?040][7 305+9# !\$ b%l>]UdvB2/0{ 4a (Z$#T/'  R4:J`@),#0@QR5+[MhQOPQ+_:F_X]AQE2OU4rA -b3cC4Aaq(^{M@nIA_Pa%Ry_ooCDdIZ s7{9X4I#bwEB2# rR5df}mh[AaP7+B4T A A"6R77R2 (z@&a5a1 !7AKb`Cost`,Enter the c associated withis process0b` $o###,9.00D7jΆӌwDu3*3u d ofstep#R;WiQg Reosourz0:numb~people0oquirtom+tetas%k0nA^i=%3`6a1j0` %Pr?opertiR`0Setustom¤e selecs2`-bb *mb?ؿ6i6p:om?8?l4  ~&8J\j oH' R  ]dt8#@k$P+ySO6aTܡݥal4;< =>'?4@ADN UFDf hZRTUU4UmA@ ?I?d Hx4 ) 4bYb))BteqYkZUHoP4,!",!4` Flowchartb`kZbrbjZbbE&z&iZ& !M" S*u )G  ?wpT]pK?w6]JThis symbol represents the start or end of a program flow.evironm.mb?ȿ6i6@ to?8?4 HD '# =ih0>T@dE=7AkUA@ ?u?Q} 4 B,A >D9A` 4u7` t:DD\f7 kpl vu 4Ub#%,& ,!>4UH"HWL4Q# / v|v-v|%) 18Hv/H$ /'){Q#14W+C`9Copyright 1997 Visio Corporation. All 2s reserved.4`Shape.hlp!#181157 305Q)H#2H"&" b$$J,&,!l>]Udvh"U  4a E(D!&?"#!b|b7& .Y4I*I'rX,^$2k8_t* f?Pb6jS94mr$S2br[RGh#| :L)߉&",!"P$U##3{QEa?O# d 2dHTOc#QXowoo1eeAdM`# \onk2brm4AaG+4T>A>AH"6772E(s51QA7A`Cost `,Enter the c` associated withris process0&"aR` $###,.0/@ 7j-CHXDu3*3 md ofstep ;̏ޅRX ResouMr0:mnumbppeople0quirtovmtetask0q(^}EMV/&QG/l6 #, H%$/?QcLp7V!$wOI2d*w5hs)kdWEAa nA^=H%D<རS` %Properti}:30Se}trustom8e seleecs2$$`u?b )QH&vR  dZAFW4 #<^?w{B Y]TaR@{+U_6aEPUFDf hZRTUU4UmA@ ?I?d Hx4 ) 4bYb))BteqYkVZUHo4,!",!4` Connectorbs`kZbbjZbb&z&iZ& !M" S*u{ mgK' %w pww=p ZJUse in conjunction with deciss. Type "Yes" or "No" todicate result.HDD &J# =h8>T YY9 7 ;AU@7?@A@?@TP} 4u `u Au  4hbJ4u7`h?gu r*0*0+ b7AC@M>4U (*?)(A,A'p'$z-'(4r'b66 666 61 67*@# LZ$8h8 bL6] h@B2rqǿ?@I0ϵ?45? **LA-0~!7i hBu .>FnShNAsh*+$'H){;Q@TCR`9Copyright 1997 Visio Corporation. All eRs reserved.`shape.hlp!#26?006`3d1E_%l>*,>UdY TYY9 75AUA@ ??P} T4 4u7` /u: 4b[bb b.A72>4U LJ4{#!($C`9Copyright 1997 Visio Corporation. All M"s reserved.4`Shape.hlp!#18035' #00"\W bdbbUl>0>Udd11Y"DaT@6bL6L6 2E44:=?1%?O9A1.K6EM=eE|2vO;4rA BCC4ai(da'_j(_a_BkyP__q4(^==љ@L?H_)\b0;&LQR/O ooa369oKf7Tfo)0g7ZAbQ%\kto0on"3m_^+4T!!6t77t"s;#%#!!7EB`Costr`,Enter the c. associated with@is process \b!` $#7##,|.0 q7DQ&Due#*B# ;dȄ ofYstepfq%#쬅G& ReosourbzE :;numb>~peoplex oquirRtoDmnteYtas%k nA^Y= (#!=s` %PropertiK:B#0Set@ustom^e selecQs̍"d`cBb mb?ؿ6i6p:om?8?l4 _ Q);M_>m w =_Hs'  NAFݥ& #4'MB $(fa٥tTo @kuo?+,6a|T$pUFDf hZRTUU4UmA@ ?I?d Hx4 ) 4bYb))BteqYkVZUHo4,!",!4` Connectorbs`kZbbjZbb&z&iZ& !M" S*  ?!4;w#\ w?wwwpppwpwbq JUse in conjunction with deciss. Type "Yes" or "No" todicate result.HDD &J# =h8>T YY9 7 ;AU@A@@ P} 4u `u AuU  4hbJ4u7`h?gu r*0*0 b7A@&>4 @ *'!)&) &) Q'p'z-I'(4Ar'b66 666 *61 "67@# LZ$h?bL6 .h@B2rq?@I0?Z45? *LA-0!7 hBu.>FnShNAshb*+$'H{;Q@TCR`9Copyright 1997 Visio Corporation. All eRs reserved.`shape.hlp!#2600630d1E_%l> $>Ud \5j T YY9 7AUA?ZP-DT!@A-4u `u bu  @4"4,%4* Zk.AE D 4u7`h?ub6#4a x @2 !)W4":,:'I>@ ?Y"'///,7?:)(&([<.?4^V4Uh$f$ *a)% 4 tNs%2 J6z2,3pg&G@b68@!q$2rq?o@It@?jDMrE??*bruLA@Y70@Bu@\4B CC>">"AB4">"dh(:`uY`9@7@7@@u`BQD} 2>"W>!@@$ V {3Q[Cs`9Copyright 1997 Visio Corporation. All bs reserved.`Shape.hlp!#18150QTSTah`l> $>Ud>! E 30202ac `e(439U3@ )Svm4FsWE h!&y( 5~BKF))/7Ap4A^IE9 #GSz3~c0C!tu!+s \i7Oc#7 W%s,sn)T YY9 7;AU@7?q@AP} 4u `u Aw@u  4hbJ4uu7`h?g#ur*0*y0 b7eA@>4U q@ ?*I)&)A,A &p'z-'(4r'\b6U6 666U 61BU67 @# LZ$h8 NbL6 h'@2rq?@I0?Z45? *LA-0!7 hBu.>FnShNAshb*+$'H{;Q@TCR`9Copyright 1997 Visio Corporation. All eRs reserved.`shape.hlp!#260063 d1E_?2l>,>UdYj TA  ;7BzA[UA? u?Q} 4 VL >-A.A74rz@m4u7` WB8.!UPVnu 4b %J& !>74 U1"222(@4 @ 4r?@ ` `%Τ%?P} Q!Uu(`7-)$)2A{#.E1Q"$7{&":$1%} "b{:#14@+C `9Copyright 1997 Visio Corporation. All Bs reserved.d2`Shape.hlp!#18140I5:)1#21"" 1"&!B7 OCe@l>0>UddE6 4a5R;U;P.(T:#? H3V  U#R4]s]J^Q5__YQQ5 kjV!m]Ae2Ro;4r3bc q(^5]!o?I Yq1%(/;Krcsqk"3vr7 {y q5{7Kk"#f~8a^fdjust width of box to change paragraph. Box_'s heBas accordingǁtext.dAhai=9 ?Y@ @pfsU2K#333u740 @a E1>n   !0ܚ+=Փ2%Hs(  ]AFL, #BB 4Cf>ao W@+ko5a-D#PU4567t4#"@.Q$@ 1HC-|$'7"AU567;t4#"@.Q$@ D'6IC-$'G7"A<t4#}"@Q$@ 'IA-37U567=t4#"@.Q$@ d)IC-$'7"A>t4#}"@Q$@ )3JA-397?t4#}"@Q$@ ,~JA-37@t4#}"@Q$@ T-JA-d37Dt4#}"@Q$@ .KA-\(7"A @$HFR@$IIFR@\'I?R@'IFR@|)?J?R@ *J?R@,J?R@t-KCRH<( H<( H<( H<( H<( H<( H<( H<(  E1/L RE2AHGBAH>AGFAHBAGHFAGNAHGRAHNAGC1HfAGZAHnAGHrAGHvAGfAHzAGH~AGnAHAGrAHAGvAHAGzAHAG~AHAGAHAGAHAG%DAGAHGAHAGAHAGHAGAHAGAHAGAHAGDC1GAHGAHAGAHAGAHZAGAH1GAH2JAHGAHCeP14o;<1=a>"AAA"A"&AAA!".AAA1AA"6AAA">AAABAAAFA5JBNAAARA!!C1\iZAeeAAfAc8nA9rA:vA..zAJѱ~AcKޱAL뱆AAA!MANAcOA_D,A11ARSA1S`TmƮAZzAUAVAcWAXAYA1[A]1^FAUiaS@a|UAAu&`X OE?@V#@;?\#@02(`A!B "EFAr$f NA45BG003@ڒlAUu"AU2CC ZA2(cUA5%h@E?3BAvAESu{sp0 Inf0?ion?mohC$[EA%T5 ]6 7$"qDJ2 eEYHA3)wB]drAwwrwH_/ %/AUQ߹T)#A3?QcuXߙFD1h)?F); T"l'&m _>?O9{&8J\n. ?\QނsY\YMy"2 hYQy5[rXtV_X%ڡ_s`How%ч4[@R'_vOf/]rerH=o/]O,fHt)Xypy5 ENDۂNS_Ʌ%&?Tw_J9ȡrsḏYȡȡR8WQ90Zpq3?@tTFdsUF|\@arݙ̱u-`u `bu`u ޓϒޓu҇`^uq@n#AfBZqm⤢??FO-CE4׊?@pL?@z@"9?Q9p 5q~i츚⤢Dx%աCLRlaMaCr`!i"6o? oLg tNZqzsK !y5K2rq_?@I&u$տ?8&>y9~o:rEqAWA@TYɅWBYC pba.aX_?_FJbqs ͅ5ьHwY3H;+=ߌ2?U@XP2!5_G@?ʯO3IS>]BV&&HO_OuB u1uCAx%OO__$9_K_${_ cx%f_2y5AFToP##q'%em/`4/F/|M/!I/c//.GW?9*See Fever Assessment GuidelinesbbOko\ooolсa1͏~Da1a1$6Hl~Jkx"[UԿ+eҟ$~Y=RU8'RHdv_a1fݯJPK("6qbgop܅qvoo~il.p2fHgzx1CUa6V7p?ϒϤ϶``A#P+?ÿ.@Rdv߈ߚ߬߾߀sx!D0ӏjMa1?A?L\OnOGgv 7U@k @@ԡ?Ҥm*o_dDai__ " s, G(:L^WUVuaȨԢ?dԭ4 @.za+y8uSu`u!@`obHxu`u [|^YrTrI,s;f,suu `1?xcu"~*GRrvh9dc-ȨFDuȧB& U%/ #Kzd߇̏ߏGSvw:rGR|H?sゥr۳!Ia%pY7 Fr D$;<3!3K~5|Xx??z A&~pa5 OO.O@OWVFa+a3:_Os?7UmiTڿJmal@e@oRopcri~,R~xmmU@#"' @gL % *Ly {@+9 qSBƘ1 ȩ11 4a} gh`2lq?߲??@AsTز Uppb&b@1U?00֥!Q !5uIOUq`FXpamUjeU,~AҔTD?QeCRѢ^ YyYdiÞi++0Q 4FnnnQq[!kQje &i@qUɐiperacillin / Tazobactam AND TobramycVanco Alternative regimens: Ciproflox/D Flagyl jGġ__^ȕb^ȴ4F/!3"QIT'A->*<FmG%? )& E7k4i/{/^Ȉ^G'7mdyvo4?Ta+HTa5D6D+7Djbid}Ao4 b^HA'ա'2'FJ-F7O3!$ 5FfArDOOK5UOOO@a'۵#h'_ribnU@QU@+=dׁd҇vpvq};GYk}oaVl bb3)`rQYQ_oyfnx@ x~-?wxnʟnf4Fjjإx%See Candida Guid=ees????OO? qY뼶%qQY__W>ɶ4Ok1]ɶ>uq0oBd&Kn?OyjoogocJ}=iDcKg)p񽱶n p@z9@ϱBpޤ<dC1 tN7`zs#z ҎQav5Ho.km;Y@Rp1؀x b v~LB'l#F˵fg$ä6Bä?3EWi{ aP+ÿ(:L^p߂ߔߦm#RU15U@ [Կ! _SKSs U __5CK:[$/6/̟U@#"d@ p 9ooo;SVBa776! 1Cv_9w`w0^T#/ݱ/ 0R/?=??4,4Ȣ)k+{L/;k+?/^`8 Co aQ2KAwait final resultsAdiagnostic work-up/AkQ7Ot[OmOOLA_OZЯ(_:_L_^__\FD3tq62__ oo-o?nebud]3voooiC½h.&@oo  Ovu"//sՉq 6 ??1>ls.&2-'z8r98,I[mqΏݱ C4FXj|ğ֟ 7I 5W1QT_O __y_ dAOײ D3tsR:RL^p//$'?2)vG/Y/k/}//b`@lQ'2N85?3Lr(؏Z?ju3v4=5v4q??D3r OkO0OBOTDapbZI{GpHfGOU@0˚G/@yکOO@OOO_Vɡ,QɡɩmU_g_y__ɠ_sx*PdQj\" >" a:2q?,>qJ? 9p1>JCyyy'b&b٧ڸtU| M`00c3=SUd^UAo=qݿZ ɥ_To%&Y?oqh@bI55U2XdX*77ݝq A]wWSIEԲKLq\Piperacillin / Tazobactam AND Tobramyc6 +/- VancoO" Alternative Regimens: ,/>)Ciproflox n +F+ɡ"Zsb qlj"Sb-_tk=QaOSj?!32A15?&`U1wau?~?? ??7-??OO(O6md"ȒdOo2X%T=Q5Tq6Tw)7Ti_qPM1"_#zVت'x弈nQqhq_VR''VVeVJ!*'fVnQw2zT_ZmRzTWoi`wuɡϦC;14vq٩11,d0g9iTĿ1s!ayu#u'`u-0`bxu-`u |1yvsQTrsu` ?;uHM0Kςe{"}mߑ߭eta+@g|@)pO0@-z@.\p1=tNo[nw#wV}ߗ阳ўba.{8ߒV8a"KƉL` L tN,7Ozs ⹣!Ռv+ÿ2r-b?@I?]&OBRM1"3-?8y6v"Za[a³ɰLx!sԿTEmaql|raem̱mwt6!B<}Ty @@iq"@g?g?-QC?Qyv%c҈NԡV@\fDD|?'}';3EFoD֖P7#<#q8 Eq/O*a$FL>@"L=3kqOX7_@I_I VRF@/B+This algorithm intended to apply noso\ ial-acquirinfections. See ac\ panying text for discuss of \ munityns5"onencou surgical pat?ients.*RnYVAoXb1E//hU1e+Q$cGO1?M6uOHEɆM6%c7k,T/?!|'asυ1eoϿ@xuinpi(toڣۻRjSRB3*9lVbNVkRN rR Tqs$Ü?_VS?L?@F0UV%cllg"!"bBTfxnFB:oKvgn#T11[egyo ~ԀZڒr]ړuA 8FOauWuXړ$NFA0#AYud=̯@ޯ&A w2r"?@UItpiuru ḴZ6d1MՃa$?3UOa+a3:(?AOWu6iT1 J=1S?dS/!X185Z?l? ~???n247@Ñ8L @O O2O@DOVOhOzONRArM_}'9Kl8Oe_<ɏ$#㳋@5@?0#:,O8ѕy9QuKQ%@3b6  o֯ѐKPakSnB2b!b"vb! v ab1$?Xj?5"&J  J'!$5= `0ut>-sU1,>1SX~=*R/HTŮ/?'q@~#T} 8dz/C/s#bEĉf "1.;E?W?-?"1RU|272O;"1eO7O9 5uOޕPiperacillin / Tazobactam +/- Vancomycin Alternative Regimenso: C@daB AND Ciproflox@nLkRQT 9ģmH!j&_8_H?޻_!3R|ZF_mU?7`ImjCR3o*X+Te5ddI6qdq7~deiAzTqh!H', BHBU v> vH1B1vfadtagoGuu&8J\tBq#vfp끅1dą1 /0BTf0)ywVU?ɕڟ"4FX1z1@կ )w?" Sÿ߱f6E!7 asÅ6j7?͚ ё!37L^pߔߦ߸Ֆgҥoo r/C?@Q}є/Tt߸'ѱ3/lL'nȏ2愮@a`@"4F@Xj|fUPƟ؟-?Qر1Dϥp oӡ.6IXW2}~3P?Oo3,ODSe1@~ϐϢϴ'/?);M_qَ!M( ];ys?QT% OG)OJMO_OqOOٯOO‘E5FGO@R-_vzQHTUH)`OX_j_ђ2Ѫ&SSѶSQ _SLo^opoᯔoooo%@& E/$T5?K+?#y!<5Of/ЅO (xOOY_s3HS?Too$eSoeowookghoe` ~5o$6Hkr% @<Հ Q $@ Qn*g'sљɏۏn-@41l>~6j|ğ֟'bLsuILXj|4D5Q<;WBQF]SpuBQ>*=ksLLTs&&&5GYkϛknpqkt0KlĶK *?0BTfxߊߜ߮,?M"b {eAlternative regimens:x`PobeibCiproflox`wajim Mixed aoao=c#` andHayh+woom8gnilj@OZcxHl|E'! 3!!V4! \#Vt$PP[ ?Y)2Y"` q՛D &8~$DiQՏޏiݰL) {OפsA!Dѥ!Ϙl!З'j%z!"FJFF!!Q*"n. cК+DV%cui5ΙͯMc[m$#Bx.@ ׿{π ϱf ߜ@Rd 1eoa3 IQ1= =.ӿc4u䯨nm甃A_AbaϘ+lTQ5$c6i27R k㔃AwI5Ϙ$iAQi SAU ꑺk ?0@A$"b"B=?=OiPY @aa0=u`u`bMu`ubk^Y1"1"u҇@`Q K#uHPcAB?8390/C60XA3e# &f8#" p%Dꐒ'@-z @"//BkpE!&//.GIR?8hBX/Ak"SSFOPtHa9@%AR<)r  tN[!zs &B1/CxED9Zd 2r_?@Iy@nEuwEwa&yglhBsUSU Xwa]0Ra8S?PŊZ3 T(WU nQ(T(80s1_kO 1$? n?]=o_q_sh2Q@ e$6HZl~WrFrAr?v //0/B/T(jeA'1%a/`@r#E!?9vI4H4v702wA??3Q373??? OK@G5HDOVE;ԎkjnOOOOOOFQSBBshQ~i_,_>_P_bYr_> N;edd[L^p$Q̐ǑOVt1ϟHU'()U*+,-U./01U2345U6789U:;<=U>?@AUDHIJUKLMNUOPQRUSTUVUWXYZU[\]^_t45#"@]Q$@ TC-<7A@ПJRH<( EtH R\,N{P @?.PDdU.PU1( UO"D&aU=QJf )h"Ty+U-x_Ʌ&!Q- H*9(TYgTEQ/,Page-1Black fillWhite fillBlue fillRed fillGreen fillCyan fillYellow fillMagenta fillGray fill10% Gray fillWhite line30% Gray fillLong dashed lineBlue dark fillCyan dark fillGreen dark fillMagenta dark? fillRed dark fillYellow dark fill50% Gray fill70% Gray fill90% Gray fill1pxl line3pxl line9pxl lineHairlineShort dashed? lineArial centeredArial top leftArial topTimes centeredTimes topTimes top leftConnectorFlow NormalFlow 8pt centered Conn. arrow endFlow connector textDynamic connector.18Process.9Process.32Decision.6Result.8Process.10Line connect?or.11Terminator.12Decision.14No result.15Process.16No result.17Decision.23DecisionCostDurationResourcesDecision.25No result.26No result.27TerminatorNo resultProcessResultLine connectorDynamic conn?ectorProcess.42GuideAuto-height boxProcess.22Terminator.28Process.29Result.30Dynamic connector.31Result.33Dynamic connector.34Decision.35Decision.37Result.38Decision.39No result.40No result.41Result.43Dynamic connector.44Process.45Result.46Dynamic connector.47Dynamic connector.42No result.48Result.20Decision.49No result.50Result.36 C``3 E3+E3+E34+СE3L+ޡ E3d+E3|+E3+E3+E3+)E3+7G3+NE3 ,]G3$,tG3D,G3\,G3t,G3,עG3,G3, G3,#G3,:G3-QG3,-hE3D-vE3\-E3t- E3-G3-G3-ңG3-E3-G3 .E3$.G3<.6E3T.DE3l.TG3.qG3.G3.G3.ƤE3.ԤE3/E3,/ E3D/E3\/G3|/)G3/@E3/PE3/aE3/pE30E30 E3/ E340 E3L0E3d0¥E3|0ҥE30E30E30E30 E30 E30(G31@G341[E3L1j E3\1tA3d1xG3|1A31A31A31E31G31æE31ҦE31G32E3,2 G3L2,E3d2<E3|2LE32ZE32jE32{E32E32G33E3,3ȧE3D3֧G3d3G33E33%E333E33CE33TE  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_UUU U UUUUU !"#U$%&Bt4'#"@Q$@ ¯C-<5D A%t4 ?_ A-57AJ@L4RLR@|56RH<( H<( JE4 RE 9 R`{N } g"4FX (h( )@%@(Qa*&u]1Pi_Ln:TWB  oR#&\pmJ! G>@Y3UF[3o0FdgMR$*NwP.FN\f) ' h1<?=2 b`?3*P}D6$6%D:`?@ABCDEFGHIJKtOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrsuxyz{|}~Oh+'0@Hdp|Michael L. CheathamG{  EMF|lx@VISIODrawingL{| ??d(P(|PXXX@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@hhh000_________@@@ppp```ppp000```000(((@@@@@@@@@@@@@@@@@@???@@@@@@@@@@@@@@@@@@@@@(((׿^^^{{{555bbb888pppPPP(((000HHH@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@hhhXXX```@@@000888@@@ 矟@@@@@@@@@@@@@@@444@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!!!<<<XXX@@@@@@@@@@@@@@@@@@@@@``````@@@{{{󿿿{{{222@@@000000@@@@@@000@@@ @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@000PPP@@@``````@@@@@@000׿000@@@...@@@@@@~~~@@@@@@@@@@@@WWW@@@"""///@@@@@@888@@@@@@hhhXXX@@@000hhh888 @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@000HHH@@@@@@XXX@@@@@@@@@888@@@@@@@@@wwwhhhXXX<<< @@@@@@000888ڿǿsss000:::hhhXXX>>>***@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@fffXXX@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@***CCC @@@@@@$$$888```000@@@888@@@@@@XXXhhhPPPppp```@@@888...@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@888@@@XXXhhhPPPpppddd````````````@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@ 000000```@@@$$$ccc000kkk888@@@$$$ccc``````hhhXXX@@@$$$ccc000@@@@@@@@@@@@ϧ888@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@'''@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@222222@@@@@@@@@@@@###GGG@@@@@@$$$ ZZZwww]]]```@@@@@@@@@hhhUUUwww@@@@@@@@@@@@@@@@@@@@@@@@555PPP```000@@@@@@@@@888@@@@@@@@@@@@@@@@@@@@@@@@XXX@@@kkk```000ߧ888@@@kkk``````NNN@@@>>>```XXX@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@kkk```000000 @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@000HHHkkk```000000kkk```kkk```SSSXXXkkk```@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@kkk``````@@@kkk```@@@kkk```@@@kkk```@@@kkk```@@@kkk```WWW]]]@@@kkkhhhKKKMMM```@@@kkk000000???```@@@kkk000888@@@kkk```PPPhhhpppHHH???@@@@@@kkk```((((((@@@kkk```888HHHxxx@@@kkk```888@@@@@@@@@@@@@@@@@@@@@@@@@@@kkk``` """000eee@@@bbbKKK@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@XXX@@@@@@```PPPhhhxxxFFF@@@@@@sss@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@000<<<```000@@@@@@@@@@@@@@@@@@888@@@PPP```000000@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@PPP```hhhPPP@@@@@@XXXXXX```@@@PPP```((((((@@@@@@PPP```888888ooo@@@PPP```888888@@@@@@PPP```((((((@@@PPP```@@@PPP```XXX^^^@@@PPP```@@@PPP```秧ooo@@@PPP```@@@PPP```秧@@@```@@@PPP```PPPEEE|||PPP```AAA666xxx______PPP000888<<<<<<PPPxxx888000@@@@@@@@@```@@@PPP@@@xxx@@@000(((@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@PPP000@@@@@@@@@@@@@@@(((@@@HHHxxx@@@PPPHHHppp```XXX@@@@@@@@@@@@@@@888@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@aaa@@@@@@@@@@@@@@@@@@@@@PPP((( gggځ000@@@@@@@@@@@@ gggCCCMMMppp@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@ (((888xxx@@@@@@@@@@@@@@@@@@hhhCCCwww@@@@@@444www@@@hhhooo$$$@@@000@@@@@@@@@@@@@@@HHHxxx@@@@@@@@@@@@@@@@@@@@@@@@@@@<<<000@@@@@@@@@888000(((@@@<<<pppHHH888@@@888@@@<<<(((000@@@@@@@@@```@@@<<<PPP```HHHhhh000000<<<((((((<<<<<<<<<<<<᭭<<<HHH<<<888---<<<@@@``````<<<000000<<<@@@@@@@@@@@@^^^000@@@@@@<<<@@@XXX@@@@@@@@@``````@@@@@@@@@@@@@@@@@@@@@<<<000'''oooCCCWWW@@@@@@@@@@@@@@@@@@@@@<<<000@@@@@@@@@@@@888www@@@TTTggg<<<``````@@@@@@@@@@@@@@@@@@@@@@@@XXX<<<000666000@@@@@@<<<000@@@??????<<<``````@@@<<<000000<<<fff<<<<<<Ͽ```<<<ppp@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@<<<KKK<<<111---HHHxxx``````篯lll(((000@@@PPP```888PPPppp000ppp888000@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@```(((@@@@@@@@@@@@ppphhhHHHxxx@@@`````````000PPP```XXX000(((000`````````xxx888...aaa___@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@ppp000YYYccc```@@@@@@@@@@@@000TTT}}}000@@@@@@@@@@@@@@@@@@@@@mmmPPP@@@666aaa@@@ooo___000^^^mmm```000TTT}}}000PPP000@@@888````````````vvvxxxPPPpppXXXhhhǟ```000PPP``````000@@@ppp888@@@```(((hhh000888@@@PPP```888PPPppp000xxxPPPpppXXXhhh篯@@@888888]]]000OOO```PPPgggwww@@@``````@@@@@@@@@@@@```ggg```<<<```PPP@@@WWWggg߯(((PPP```000XXX``````@@@ @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@```QQQPPP```'''***XXXXXX``````@@@ hhh000@@@׏ppp@@@000000000pppppp000xxx(((xxx@@@HHH``````@@@((( ׇ000@@@@@@@@@@@@888wwwwww{{{hhhhhh000'''ooobbbppp ppp@@@``````000888@@@000@@@@@@000000@@@``````@@@000DocumentSummaryInformation8H1Tablew SummaryInformation(DocumentSummaryInformation84PagesMasters Page-1 Decision Terminator No resultProcessResultLine connectorDynamic connectorAuto-height box8_VPID_ALTERNATENAMES_VPID_PREVIEWS_PID_LINKBASE A Oh+'0|F&HvaR«JsgA>D}-\1wLM..:g% ~R 6(1;H.Vs/xמ'=Ύ,~m3N+A9y^U [TzAޚ7뽽!^2^n7gY`0/}Ad} 2;*bEأsɯʄ _=,le/_IUQW%4>ۘ}w1{?g?vti-^/} c7 .} ݢ?~z4x}hOgGU-B|֋Ǘ>oro8#Ǘw_-xB|> {~W9X'E. @a; F);z2ׄ1LBhmrC!$}'ݣB{1wYhU1&6Z ̝pRXo;R=$2d 8;rN䷫e?ioXń7MDOoF?wR=0lTSdv/}לlzΑȱߜ%& ?_GfsCF@XMOiUj_k!}#e`dƗaĀ h -6#UZ{;#tAB,7ɴʁ;;(!My#%9 , vM9sF#ȡfB, ) f0&A'L ]2u:;ι;n q1;][oW?W|W}η}7S&uI u(z? 8vPl€f4nϞ G0{Fݷ'j5O#2aRw u}!Mλ!#=e]u-9",DŽbXwq| %iNcd´+>9V|1Ʋayh9r5}NL?&3عk뽻5~r߰GrLkDz9Mܞy d2qr&X6; gJ]ؚX<^Xsj斆]fKW,Od( xo 5FȟQ61mNȇS_G&ZT}AG/?"2-*2KMÚM5"7'݆!эf 3oF] s)@?)[ꯐY}}N!K?"sU7ћn#̘z D&sC^> z22RA.,wdG֤=SZ~HǎI@V~<+8y3ڭVɻ"SD*6E^=}ys>.;:2x] q2=r 2 +K*!kY/Rq+qwWgFy='Mʸȏ_@O"f }MdvvH9.vß<]de)d'ɜNίU7' e A*+{\+-t^nfm|8Aпk8}+yWA쀓G7Ow}+M\,8oURߪo(g4(vU#yзW}7,ppRʶK#J$yPnjڄ~Ɇ5Cq4,d/dj_ngurz dk?%}Anuǎg珼L5 RUG.ܱ#<ȝU{+{׸tj#!/hm GW7hWTqB_;n,oc{ V7].FE"(+['@Nognޅ7nS7&& ;Nv<]s Btnt_eVәXEzF+(ͬCt\l=dqrґzEu4cW뼽S 7ґ?F檶"nDFo 8)=2%2iIW]Fƽ{ d꾿y'ez`2wdJJHCbeOvs| !Y/cת(g2ө.@gW 4_HUY1]sCdʖ2 X9U"k EP =J݋JY,`yp~V>zOuu& mw#Wg&d¹ȨMIH[y]?l2+u12ѣאzR3z߸}~O?],2qEd!W~F~qȚo?v޶ȌnȠ=şcg$B\|:WAoݜПJA6ڬ|>m4D& FENA1RלΕpdbR򲪕Jv Sf!@OygX1cRRe;YH[kesrpѯ^&DX1\/ϋUR݃o1zo]y;mqWhS6i#ClD@kؖH7´E:"MADBFt . hhx"i.7 !~kr_fy Z;4oD֋ 9ԁɬW ִNȽj4X2j;ȄK¥n'|6qJ4YHuw(O|\<-Bysn:[:f9Vd7|, _q.Vc_Dκ;,ʝc 5|ŮfLez -v >d_zWdWmhȗŮbɞ ޳{2''Z<_:ﵕ4N+g2K7h7M󬭼9Oqg|۲+ } r|۲]o⸞^z y-=P;)jyVbG ֜ZG8oyOG4^oNf/ȋ ;_(PUzE _4% sik~Y2'H֫ pӼ5ƿ˚,Y͏Yd"^we(\=>:@m1>՛s aa .hK*ێg Poe+pu-)ڕҬy?'S\Saʋ_*4S3*{tYy Y9/ [VEȿVRܬG:T2PG@91B;f^tdd܂KrOnCuY@_`v'a32`;.V[=O׭C@]J:S< "!8<H8ʎ Ҡpۑ2Ȋ/bZ_s0֠n8G!@ i!o1jsvA&ix&\զ3ro?dboN$_B,8Sy[hD@;υ^T0וJ߮qK.K'Q'\vcY{w,iSȾuV2 =-fttta;fG<\7>SvNF7B>$b h LYYD:~3 ȑ'hgfh)+H*m|gs=y|WF;Tư$6} ;8$|p6A}i:F̌OG!o_% "s6BC&!M㞧2M~HǦST} |¼,W,4dq$b X[F}FuvѺd FfB&+&Sogsԭ42d`9w$/j .{lX Kk$R;Ӻcg|l9;ۍTBu# >vμY0;kδilll`0v6nY-/ocyl6S;Q;nyS:_m, Wv_^bm\l \o簺<ܑms\#Ɲ;W݂mrݐv4&a=G,N' =6&zkdnlM"GWǰCxWxy||f5W>)x=7!yZ|4|O<4GKHϳ6GZt`ŘоbByƄlW>;͋ϑ >>/IJ_qr>`Wܑ2ȞiG4ً-yS\fv6@15 ˸N( #dh;z[]u=l~ fanT֑ D>܄lv$4d{CNdk{d7]mXK=79T6*T<{D ; ǪJ8N$" q)cI6ʱ)1h-HA__ T 2Zdo7$Ha fNL 2anKdԋmg U^ٲ\<}AQrW/*.,ٝ4.jg?Ȑ2=$i O(y,ˢ #H>c =[Vk麽dIL'G"ˬCg2PrnM=FSGilY:-]ހ1k_IQ_t|m$X^RGm7|J_Dy~6o2>G:gbșF:;Dツ| _,C 9yndqYLNT#%):[&K0olMF+ښ05YIm3z]r4F:CX1e>y.o~ߖŲ /K4l m7\sGΚMnW>) wgpksw՚[ߓ"U}U{Ut^`v??X`g<g$?!oe$sGJ ^oq|q`"mZKtZYnIr۸Msmzb2~1rAFޢY+wVA:,5i^M, wMgy9-sުh[LQ{~tRI漕?O<>p@0ÞގWTW4 q+8^QvaI?6O$Beγ{ 9^SHz^3<ҫ4ν}b}aΪGyq~vޞm ~ Ҡpۑ2? e2+M0nT$l=h>Zz jW>;c,؂%Yhx9Hp|NR%Y Ki {7":z&۝& }1 9Sܦdqa:S ,?a62Ǥ,Gef.ؒ܃1u)y+q0[ǃ PNG1W&׎e=z8)`C}5K~͞- YR5{X2γd[2J2p(xd6gQ&πr`eks|3/t67 Ƿ+ @VÆ3hWȜ%iSt@ke*|_۾ EmS7[8q6i ƭ5vk37u߃qw e2hj(4L87)L[̌N'#6 :2392yF$djT׏ndDzKn6SQMqUt2\5m7wIz]u Cӑ`V `?WF^|q5~֟>4XBszJW`;g߉F軉fpg\UsR[~)~a͹xxtJxcW +*ʇ10~=F# 6}WHB) 9_dD@=+-DžL1'o,4ǑG*_jo#QpG_ƑQи8ܾ5ȤpF8w8H##p8V#ǑWti7kqdïqm1O.RY6yWҽ߼Wkӳ<ѐ \9Ӑ4K|lS;1aP^;  G.]?D=g*V~)=),{+gmh17rZ]nkz3YnTҾ**]oܞS|F<1߫8;G\mi7j]dƿL7)r *VBGϮL8O4k!K[F"s$!ӮF3:! a?,_9P:z*\$ n_&V:R}%I%+䝙|la"ްdO a*Y|GXlz|c'}reZ F{&7m<=xk͆NFYqnɩFѿ;쇍чhu,3Yͦ0nnΎ_d+D=kCZgٞ~aub{z*Ef3c Jzj4MѸb= 6{.Q=5ݫ'_POǬ?{y)w)wi=7yܭSPczsvoQNXA;dm 84s6̧/7|p_A t캨g1@|PuK]~ -}zo˧Xo8^yo 4Y!ñ qcN^{ }nKFp@[(*ĶPˈl7#ܙm珏4}Bۃa +fe8{Þ=[:-4n_Cß}8`x(c./=6pMۆ;-8gva;('s >_+EA= Et*M?7h9׎.'̝觽p mȨ 37 MN# yrqG&VG#v9&C?JրBE;dYf{u*яf]f0[{eĆZfV3-i}32g/^VɾHHG _IF2$m icw[kaM쒮k}7ׯ 6_k5Zײd?kG-\w/pu#p?:Wځ@" ;YyjfXHq1XHVdiM&V*4Od\07R\ 9=_ >J|mEF5pͩ>(l,Ek- f3kI*2gxj|pj.2[wBfUE&+B(϶Ha@g]OdΒta2#yTǒ4(>l·gŽ@+?92r~￐@Mm4Bn8!o,nqȈ~i$o9m$?@XvD2~֤fu`muin ۴wЙG%~jdNH#dZ~4(@7$ l}׋^e\؟+Z{;]/ ~5"rzG{zu~)a8ÞK ?nѿ`]v4|K\@o_uܩs2dWga_Zr5(ϠQ1u v܃s] ?Da:/0rK܇miYfH?ݍb'I7Y!598~ڇ-^7t]Dz~p&KUH vPY/a6=zLȄ_ y'HvRAG2a^vH2=W bZZ oNDdu; R}2}^p/4΂\Q]Z*Hӽqo戴m,1[tz{2y:\׻z ޮӍdiY/Yz.zZ|_ۦz&v i'iq.Lz鄨.oޚB 2yk!Бq t>N+kkjk.+>׶*}uϵ}FKߡUA\Su,)+=¹Smvz'/gȇ11W!UBVj,Jg颤ae_Lb l-Rpi -B ,pvK -ԡVQ gsgʾ+C'm.@?_Ix_묰5 ske&>qo(;,iA3O*QsITzd$`z=WiXs?ӎsryG_|e8Ν)䝳0?]o#ywwVߏ.կXaȾžyBCyy"|z5e>{q׆T gC㍐ȹrG@쀘py@'"ѾJY|*W;+5dgJAp;,u{@~6ќ@ZO0As-h:Q] WEf/G r}Lq ;| ]oWӀv̱){sؕy7sK?[vr`A/^UhLYA/{^wlhḑlTZt|=YdGi/.{v.ls[=P7iCjl xX>ȩo-帊r<lLL<7)iAwʆ&vmd;d;d;d;d;l4_'&ÇXߓؼVA&LS=ǧh)(,2vRHΏMNuY7E#$Osf6INJElDLmXZy.~վ%WS*mԫ;^d%ju[ ǜjLSve M<*yJGeB%K]6guBrXWcA.2'ʏ.mQ[ŽXn"{=̪֐J<МX+ݕ(dd&FZ푭:#^]\>yƃ)G 򈧍<2`6Fa%þ9}%6 A8V#Ƣmfک~(sbdU4Fc]]qs9#-D>|~1r 74\ZGe}[>??zϳȨZPuoInV/#s^Ȭk*dȌ!Q<)Ecl/zZK<^凴..aMN*cQX;l%lKt3-1ؽu%rZY&[dz J䁯?DnL@܊TڎZu'P/؃\# Y]6GA0)p3szNȾ|aez`\dnNH sy0vLW')yܬUEm[jXomL4. (ȿ2]Lz'>'^^bNV~"OBf/FkՐ k"E<ߩRv12x3dFs 2~rph Z<2Ը-rTbd3fKSN`||$?X('ħģہ,i*Cހ|b5`m]K>6p?d֪ȌkS6 e )"2v!݇< r @vܚՉ ['ofr=w=WjHĊȤ^+qȚW!"Vtdk-v̲ _m#,CZ4 nk1y45[Hϱ_7[s~ti~Z`&[Ȝ{kmD]dTw`[HЦZ<>aȂ.Cy,nw+6܋Y~CΫS_C"BJ{)N>AQ=U"7-EJ *O]%^g?qHUz~&2?±/|t@Us&TDJoGUd@dj ͉"D!7A51"jl/kwtdW]Ma2 kvCȮC>껢MGԮV*l50ھtzaԟ)KlkޟsZ^T\2'ĆYʧ3 :9rb[^d.'=l`\0EsZf3Zr7DH̜I#>DFy~L8w܇ =qP2鵖ZL%/zs5bZ^@ uCm[l͵ 'RHbDз֦_tP*@ 6t@iA 6t@iA ;c>ANc_"eE۹ rߪ:M׵]}s?gzOz?3> zDBq'wJȖȴHWt5RXLXT^;DoK--kߑy~.^stGwk o]GU/{,OK^2sI[@A =0@A =0@A =0} z`sK׳=@遠Fwo7$;"|} rO OxmdpӺC c4D~|6$Y~rHHV܈Sc]y.X({O[zkw+GWy4О,l,w!-G^ytƝ!kz[8dȫ{䦝yHe}{ z|mA+LBVlܘ2 2THX l ;7Bi<\0' %}2yZK crZK&v8ƶdIkuX\>yZK;YNkiߑkifqf;sIҶcs~sOK s;k-m7Fh赴TY1|Lܫgܫ}S.m= ki,Zڼٱ\Kmq7")pXKۦ1^_Kۮ ?Y0OveW1ZU^~x c@GThbmM[LNC >'E6UZJyKnj>t͢ mmh 9ddc6ڈ/7زJgPq-DJQ7}I#=?Rο */#sY_'.}}.2|\y{ȃ}"7ŮBnl@n$~·A rl#;ސCWڷ~E:~}V}[yQ{π?~ G_zK{.3) ^L<;2~gȚWD*GQd?n#+[o!>3!>@DlGdȍ>55#~0!k`u`ҼkMΎ-It}{ k6:;Op~S8\~"t}/H q%ƙ^^u}_Hק*HKTTT>F]oq>K dEu}`䩮٪+::ZmD3[H먓cu%% Igt~\7 ޸lJ wmd{t_:$y2HHߧ"> ]~9u}~t} 1y(c\+<ưnQ^euIccZ-_B!3BLAByi04[ut]ΤQ G;H"#/$PȄS9H=4A/&1)i"vsMd2.iZgeT6ug9riH夿TL~-Q75K둁[R>nӑQ#ꃹO[ȏ8[}ZsKi 湲ҧh#b<+bf3N0J{en z{͹gB +g# iHȴ{BE^^L[V?9r^hbbW#ۤxڤ B6)A`^pK$&-m?]fR#u]?􀕍yȴ; 2_H!U̼L^i]-S)]i3.+Ƣ8e#9߯Dv[̐®}]b}]w2Gg3i;^l;|¬Y:@3Ic!1c\ )7٪x*y-,<*z;ƥ~ݼ;.ߑ~hIN_=O_ K(+,ƙ>GyY_6SNven+X6w) e-9|aV(ܗ$g=vĮ;Ʋ#Ih`|";h ͜oxoñ'=XhfkCO˵;ĭ#GN̯t8S5 k4(CsOr~䄷g"]^\8z.^Dv9䟾yma'^wC0[#%KyH݁[I!W r}N/*^jc0qu]d!_#hA~*ٴY7hEY1U }%@yzWdݑ_|2ס~EǍܝ2UO`>F p)~E2|il+ODv k7`\y|w 3!Gkњ0]z1q>ltL3_!Fdg +kT̟byCNkK{WJ (ʐNXPLw 2cq$g(a"?=@0K%HA8nȟu3Fј[&4F9MʤĻCUn\;#F_ !q! zG[(r陖m{r$˜ks[DY ė?AvI{/zASo"F\jߑ[H{\QG!;5uG4HEPw!n\3ahLF׵WF?Q׊#΋;"֕D\}?rH`sY" ߭ɵ,Kny*kp܄{CG*c}J<RYX;<גYw d"~V RT[ s`v8Xq^9iƨ~@7R1[N d_Fot5۽#3[OG: XiL %_C֮`2u{E-CNKG~]?bw'ϟH;/sBzS߹UDDG F|'iFM D=)|_#bf/.6'FDE!V +=Kҁ>\yr y#>Hovt^ltl;mKd\7>.!oͣ6%m5nJM[nf2P*W*l65iHe`3OOG=i_m-"7XSϽ0^  ,8 X d p |ICU SEDATION GUIDELINES Gail Gesin Normal.dotMichael L. Cheatham, MD4Microsoft Office Word@NSI@o_@ ċ@ő/U՜.+,0 hp  ORHS3c ICU SEDATION GUIDELINES Title  FMicrosoft Office Word Document MSWordDocWord.Document.89q8@8 Normal_HmH sH tH F@F Heading 1$$@&a$ 5OJQJF@F Heading 2$$@&a$ >*OJQJ^@^ Heading 3$$$d%d&d'd-D@&56OJQJL@L Heading 4$$@&a$5>*OJQJ\F@F Heading 5$@&5>*OJQJ\P@P Heading 6$$@&a$6CJOJQJ\]J@J Heading 7$@&5CJOJQJ\^J<@< Heading 8$@&5CJB @B Heading 9 $$@&a$5CJDA@D Default Paragraph FontVi@V  Table Normal :V 44 la (k@(No List 8>@8 Title$a$ 5OJQJRP@R Body Text 2P<^`P CJOJQJ4 @4 Footer  !<B@"< Body Text$a$OJQJ4@24 Header  !8J@B8 Subtitle 5OJQJLC@RL Body Text Indent ^OJQJ.)@a. Page Numberj@sj N Table Grid7:V0pdp*0*23;57DVW _CTz ab#$/n,opx/0_m67R&'(/I_`mYZh / 0 8 !6!b!!!""N"O"d""###'''''5+6+,,,///Q2R266::[<\<W>X>Y>>>>>>>>>>???4?>???`?k?u?v??????????@"@#@$@<@=@G@l@m@@@@@@@@@@ AAAA2A3A4ABAgAhAiAAAAAAAAAAA B B1B;BNJNRNwNNNNNNNNNNNO OOO&O6ODOEO\OsOOOOOOOOOOOOP-P.PpPqPPPPPPPPQ(Q4QX>Y>>>>>>>>>>???4?>???`?k?u?v??????????@"@#@$@<@=@G@l@m@@@@@@@@@@ AAAA2A3A4ABAgAhAiAAAAAAAAAAA B B1B;BNJNRNwNNNNNNNNNNNO OOO&O6ODOEO\OsOOOOOOOOOOOOP-P.PpPqPPPPPPPPQ(Q4QHUDW[]_[g!lasx=AEHLQS_mt #!!o"_#$(&&Y'/()d*/FFG>GuGGG"H@BCDFGIJKMNOPRTUVWXYZ[\]^`abcdefghijklnopqrsuvwxyz{|}~x?dddp: ]df}!!!!  ,b$QGiIHt֨n2:  0e0e     A@333 Ao 8c8c     ?1 d0u0@Ty2 NP'p<'pA)BCD|E||@H 0(  (  f  s *333o B S  ?5pH~$NT )i)a)k)7:)k)6):)Lac)̬:)4<YY c ccdddddp YYcccdddddp :*urn:schemas-microsoft-com:office:smarttagsStreet=*urn:schemas-microsoft-com:office:smarttags PlaceType9 *urn:schemas-microsoft-com:office:smarttagsplace8 *urn:schemas-microsoft-com:office:smarttagsCity9*urn:schemas-microsoft-com:office:smarttagsState 4   bk2<R]$"'DJKM6A/;n} k!r!s!~!!!!!""v$$'(++Q3]3????????????@!@=@E@@@@@iAAAAAAAAA B1B:B=BMBNBYBIMNMOMZM\M`MoMtMuM|M~MMMMNN.P8PXRbRSS UU]UrUVVVVVVVVVVVVVVLWVWXXoYuY'Z-ZZZZZ[[[[\\&\*\\\\\]]^#^^^^^^^^^^^[_^_h_k_``-`Z```aaaaaaDbMbmbrbbb-c6c d d"d"d#d#d%d&d(d)d+d,d l!lp1 4 ##66==iAA B0BXXZZ[[\\ ]]]]__-`Z`aa d d"d"d#d#d%d&d(d)d+d,d l!lp333333333333337D_CT K#$/px7(ZhO"d"'',,Y>>>#@$@@@iAA B1BBMKoKLMMIMMMwNPPQaQRR&SSS6TETTT.UUUUVVWWWWWWXXVYoYYZZZ`[[[&\\\]]}^^[_}_ `-```aa7b`bbbc)ccd d d"d"d#d#d%d&d(d)d+d,d7dJdfffffgg,gggOisi l!l'lDlElMlun}np d d"d"d#d#d%d&d(d)d+d,d l!lp%/%?E  b48|z%X|n|7 { ZIHh  $x!&eag">}&B4)IMPB*˨|jc*(n$j40 G1 77& %}9&hy`Vx= d= IZpE x F 8SM&eUUd:ZV NMVX|nnX MZtxf,N[ dc MAez@IYeP./hZ* xZkt VT}:* 88^8`OJQJo( ^`OJQJo(o pp^p`OJQJo( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJQJo( ^`OJQJo( ^`OJQJo(o PP^P`OJQJo(hh^h`.0^`0o(. hh^h`OJQJo( ^`OJQJo(o ^`OJQJo( pp^p`OJQJo( @ @ ^@ `OJQJo(o ^`OJQJo( ^`OJQJo( ^`OJQJo(o ^`OJQJo(hh^h`o(.hh^h`.h^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hH hh^h`OJQJo(h ^`OJQJo(h ^`OJQJo(oh pp^p`OJQJo(h @ @ ^@ `OJQJo(h ^`OJQJo(oh ^`OJQJo(h ^`OJQJo(h ^`OJQJo(oh PP^P`OJQJo(hh^h`OJQJo(hH^`OJQJ^Jo(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJQJ^Jo(hHo^`OJQJo(hH^`OJQJo(hH^`OJQJ^Jo(hHoPP^P`OJQJo(hH hh^h`OJQJo( hh^h`OJQJo(-hh^h`OJQJo(hH^`OJQJ^Jo(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJQJ^Jo(hHo^`OJQJo(hH^`OJQJo(hH^`OJQJ^Jo(hHoPP^P`OJQJo(hHhh^h`56B*CJOJQJo(. hh^h`OJQJo(@h ^`OJQJo(hh^h`5o(.hh^h`5o(.hh^h`CJOJQJo(q0^`0o(. 88^8`hH. L^`LhH.   ^ `hH.   ^ `hH. xLx^x`LhH. HH^H`hH. ^`hH. L^`LhH.h88^8`CJOJQJo(qh ^`OJQJo(oh   ^ `OJQJo(h   ^ `OJQJo(h xx^x`OJQJo(oh HH^H`OJQJo(h ^`OJQJo(h ^`OJQJo(oh ^`OJQJo(88^8`OJQJo(hHpp^p`OJQJ^Jo(hHo@ @ ^@ `OJQJo(hH^`OJQJo(hH^`OJQJ^Jo(hHo^`OJQJo(hH^`OJQJo(hHPP^P`OJQJ^Jo(hHo  ^ `OJQJo(hHh ^`OJQJo(h ^`OJQJo(h pp^p`OJQJo(h @ @ ^@ `OJQJo(h ^`OJQJo(oh ^`OJQJo(h ^`OJQJo(h ^`OJQJo(oh PP^P`OJQJo(0^`0o(. hh^h`OJQJo( hh^h`OJQJo( ^`OJQJo( ^`OJQJo( pp^p`OJQJo( @ @ ^@ `OJQJo(o ^`OJQJo( ^`OJQJo( ^`OJQJo(o ^`OJQJo( hh^h`OJQJo(h hh^h`OJQJo(h 88^8`OJQJo(oh ^`OJQJo(h   ^ `OJQJo(h   ^ `OJQJo(oh xx^x`OJQJo(h HH^H`OJQJo(h ^`OJQJo(oh ^`OJQJo(hh^h`CJOJQJo(qhh^h`CJOJQJo(q ^`OJQJo(h^`.h^`.hpLp^p`L.h@ @ ^@ `.h^`.hL^`L.h^`.h^`.hPLP^P`L.h^`CJOJQJo(qh ^`OJQJo(oh pp^p`OJQJo(h @ @ ^@ `OJQJo(h ^`OJQJo(oh ^`OJQJo(h ^`OJQJo(h ^`OJQJo(oh PP^P`OJQJo(@h ^`OJQJo( hh^h`OJQJo(h hh^h`OJQJo( 88^8`o(.h ^`OJQJo(h   ^ `OJQJo(h   ^ `OJQJo(oh xx^x`OJQJo(h HH^H`OJQJo(h ^`OJQJo(oh ^`OJQJo(%nX|7%}9 774)ZV$j40}&,N[dc`Vx=thpEG1{xZk bUUE IYe/%z%NMV4ښMAe$x!8SMjc*d=VT}MZZIPB*ag"x F@ښ @h ^`OJQJo(%%         )|        )|        4.        )|          N ]-T359>s_"v([  #$/nopx_&'(/I_`mYZh / 0 8 N"O"d""##>>>>>>>???4?>???`?k?u?v??????????@"@#@<@=@G@l@@@@@@@@ AAAA2A3A4ABAgAhAiAAAAAAAAAAA B B1B;BNwNNNNNNNNNNO OOO&O6ODOEO\OsOOOOOOOOOOOP-P.PpPqPPPPPPP(QaQQQQQQQQQQR"R#R-R:RIRWRXRRRRRRS SSKSSSSSS6TeTTTTT-U.U8UEUPU\U]UUUUVVVVVVVVVVVVWWW W/W=WKWLWWWWWWW d"d%d(d+df lp@ddدdd@{pP@UnknownGz Times New Roman5Symbol3& z Arial;Wingdings?5 z Courier New"1h N W-&-/U3/U3$4dcc 2QHX?s2ICU SEDATION GUIDELINES Gail GesinMichael L. Cheatham, MD%                           ! " # $ CompObjq